Eureka-Singapore
Merlion School on Translational Medicine

18 – 22 November 2019
One°15 Marina Club, Sentosa, Singapore
“Translational Medicine (TM) is defined as the resolution of unmet medical needs through the use of technology, creativity and scientific method. The field of translational medicine encompasses molecular medicine, intellectual property, financing, regulation, preclinical and clinical trial studies, among other disciplines.”

Unlike traditional courses, the Merlion School is tailored to individual needs. Expect five days of complete seclusion from work and an intense experience with the expert faculty members. Merlion School is not solely based on lectures but on learner-centred discussions, mentoring by internationally recognised leaders, and exploration of real-life case studies. Skills garnered from this programme will help individuals and team members to address the challenges facing drug development today and bridge the divide between concept and patient.

The Merlion School is targeted at researchers interested in translational research and looking to further expand their skill sets or individual career development, be it in research, academia and/or industry.

Participants can expect to:

- Analyse the business, scientific and regulatory aspects of TM, and develop critical-thinking skills to approach and explore the challenges
- Examine case studies, and develop creative problem-solving strategies and novel skills to build new kinds of teams
- Hone their abilities to communicate effectively across broad audiences
- Be inducted into the Eureka Network upon graduation – having direct access to a vast network of accomplished peers, leaders and partners in TM – all building bridges and closing gaps to form a global community of TM professionals

ABOUT EUREKA

The vision of the Eureka Institute is to develop translational medicine to address unmet medical needs. More specifically, Eureka’s mission is to build and foster a global community of translational medicine professionals to advance the application of biomedical innovation for the tangible benefit of patients and society as a whole.

The Eureka Institute is a non-for-profit institute founded by an international group of leaders in translational medicine. Eureka’s overall strategy is to catalyse, integrate and impact education, research and policy-making in an international translational medicine ecosystem that benefits society. The institute does this through education and building a community of translational scientists.

Among the activities of Eureka are an annual International Certificate Course in Translational Medicine in Siracusa, Italy. The 12th certificate course will be on March 29 – April 04, 2020.

Eureka partners with major universities worldwide: SingHealth Duke-NUS Academic Medical Centre, Stanford Maternal & Child Health Research Institute, University of Miami, University of Arizona, University of Toronto, United Arab Emirates University and the UMC Utrecht. Nutricia Research, Parent Project Muscular Dystrophy, Nature Research and University College London are also supporters of Eureka (www.eurekainstitute.org).

Requests for reprints or reproduction to:
Eureka Institute for translational medicine
Benjamin Lim
c/o TII, The Academia, Discovery Tower Level 8
20 College Road
Singapore 169856
info@eurekainstitute.org

© 2019 Eureka Institute for translational medicine
All Rights Reserved
Dear Participants

The Merlion School is an initiative that is part of the partnership between SingHealth Duke-NUS Academic Medical Centre and the Eureka Institute for Translational Medicine.

Our mission, which we are profoundly committed to, is to change Medicine by harnessing technology to address unmet medical needs. Our Ethos is “patients at the heart of all we do”. With this in our hearts and minds, we aim to be transformational locally, regionally and worldwide, by inspiring and catalysing growth through innovation, education through experience, and transformation through creativity and resilience. A major goal of our Academic partnership is transforming medicine and improving lives. Truly durable and meaningful transformation requires people as its foundation. We are proud to contribute, through this Merlion School, to the formation of the leaders of the future: YOU.

We welcome you with open arms and a warm smile for an exciting journey together.

Professor Ivy Ng
Group CEO
SingHealth

Professor Thomas Coffman
Dean
Duke-NUS Medical School

Dear Participants

It is my greatest pleasure and honour to welcome you to the Eureka-Singapore Merlion School, organised with the SingHealth Duke-NUS Academic Medical Centre. Translational Medicine faces many challenges and the only way to solve this definitely is to work together and find new solutions for the pressing problems we face. Eureka was founded over a decade ago to do just that, and to empower young translational scientists to overcome the many hurdles between bench and bedside. One of that is obviously collaboration, and the launch of UCAN-Asia is one of the hopeful developments of the last year.

Already it has become clear that many of the most promising new advancements and opportunities in TM sprout from this part of the world. As an example, SingHealth Duke-NUS Academic Medical Centre has been one of the first partners and promoters of Eureka. It is clear that Asia will play a pivotal role in the future of translational medicine. This school offers you all possibilities to explore and find your own personal role in this exciting field. A line up of experienced and innovative leaders in translational medicine is ready to help you to take the next steps in your career. I am confident that this school will offer everything you need to become a successful translational researcher.

I wish you an inspiring meeting!

Berent Prakken
Professor of Paediatric Immunology
Vice Dean for Education, University Medical Centre Utrecht
CEO/Secretary Eureka Institute

ABOUT SINGHEALTH DUKE-NUS ACADEMIC MEDICAL CENTRE

The strategic partnership in Academic Medicine between Singapore Health Services and Duke-NUS Medical School builds on the collective strengths of the SingHealth Group and Duke-NUS’ research and medical education capabilities. Together, they create a vibrant academic nexus for new discoveries, learning and care innovation – and bring it to where it matters most: Patients. The Academic Medicine efforts are enhanced with the establishment of the Academic Clinical Programmes (ACPs) and joint institutes, including the Academic Medicine Education Institute (AMEI) and Academic Medicine Research Institute (AMRI) which facilitate the active growth and development of driven scientists and educators into the SingHealth Duke-NUS family (www.academic-medicine.edu.sg).
Speaker list 2019

Salvatore Albani, MD, PhD,
Director, Translational Immunology Institute,
SingHealth Duke-NUS Academic Medical Centre;
Senior Consultant, KK Women’s and Children’s Hospital;
President, Eureka Institute

Scott Compton, PhD
Associate Professor and Associate Dean of Medical Education, Duke-NUS Medical School;
Deputy Director, Prehospital Emergency Research Center;
Course Director, Merlion School

Gordon C. Baylis, DVM, DPhil
Associate Provost for Research, UAE University

Ann-Marie Chacko, PhD
Assistant Professor, Cancer & Stem Cell Biology Programme;
Head, Laboratory for Translational and Molecular Imaging (LTMi);
Co-Lead, Cancer ImmunoTherapy Imaging (CITI) Programme, Duke-NUS Medical School

Derrick Chan, BMedSci, BMBS, MCI, CSCN, FAMS
Senior Consultant & Head, Paediatric Neurology, KK Women’s and Children’s Hospital; 
Research Director, KK Research Centre Academic Vice-Chair (Research), Paediatrics Academic Clinical Programme;
Deputy Director (Education), SingHealth Medtech Office;
Director, Clinician Innovator Development Program, OACD, Duke-NUS Medical School

Valerie Chew, PhD
Assistant Professor, Duke-NUS Medical School;
Principal Investigator, Translational Immunology Institute, SingHealth Duke-NUS Academic Medical Centre

Chong Yap Seng, MBBS, MRCOG, MMED, MD, FAMS
Dean, Lien Ying Chow Professor in Medicine, Yong Loo Lin School of Medicine, National University of Singapore

Wainwright Fishburn
Partner, Cooley LLP
Capital Attorney, Vice-Chairman Critical Path Institute;
Chairman of the Sanford Burnham Prebys Medical Discovery Institute;
Executive Committee, UCSD Moores Cancer Center;
Founding Director, Corporate Directors Forum, BIOCOM;
Advisory Board for Tech Launch, Arizona;

Florent Ginhoux, PhD
Senior Principal Investigator, Singapore Immunology Network (Sign), Agency for Science, Technology and Research (A*STAR);
SingHealth Duke-NUS Academic Medical Centre;
Adjunct Visiting Associate Professor, Shanghai Immunology Institute, Jiao Tong University, China

Gianfranco Grompone, PhD
Discovery Nutrition & Health Science Lead, Lesaffre International, France

Robert Kerle
Head of R&D Solutions Southeast Asia, IQVIA

Carolyn Lam Su Ping, MBBS, PhD, MS, FACC, FAMS, FESC, FRCP
Senior Consultant, National Heart Centre, Singapore (NHCS);
Professor of Duke, National University of Singapore (NUS) Cardiovascular Academic Clinical Programme;
Director, Clinical & Translational Research Office, NHCS;
Director, Women’s Heart Clinic, NHCS;
Scientific Advisor, Clinical Trials Coordinating Centre, SingHealth;
Affiliate Member, SingHealth Duke-NUS Institute of Precision Medicine;
Associate Editor, Circulation;
Associate Editor, European Journal of Heart Failure

Lin Xiangqian,
Group President & CEO, Esco Group;
Managing Partner, Esco Ventures;
Co-Founder Carmenix, Maiden Therapeutics, Carmine Therapeutics

John C W Lim, MBBS, MSc, MP(M (Harvard), FAMS
Professor of Practice & Executive Director, Centre of Regulatory Excellence, Duke-NUS Medical School Core Lead (Policy), SingHealth Duke-NUS Global Health Institute;
Senior Advisor, Ministry of Health, Singapore; Chairman, Singapore Clinical Research Institute & National Health Innovation Centre

Fiona Loke Wei Ling, BS (EE), MS (EE)
Singapore-Stanford Biodesign Fellow 2011; Senior Manager, Medical Technology Office, SingHealth;
Co-Curriculum Head, Singapore Biodesign

Michael Howard Merson, MD
Director, SingHealth Duke-NUS Global Health Institute;
Wolfgang Joklik Professor of Global Health, Duke University

Steven Myint, MD, PhD
Chairman Karoo CGT

Ng Kee Chong, MBBS, MMEd(Paeds), FRCPH (UK)
Chairman Medical Board
Senior Associate Dean, KK Women’s and Children’s Hospital (KKH); Adjunct Associate Professor, Duke-NUS Medical School, Yong Loo Lin School of Medicine, National University of Singapore, Lee Kong Chian School of Medicine, National University of Singapore

Joanne Ngeow, MBBS, FRCP, MPH
Head, Cancer Genetics Service, Division of Medical Oncology, National Cancer Centre Singapore; Associate Professor, Lee Kong Chian School of Medicine, Nanyang Technological University

Vicki Seyfert-Margolis, PhD
Founder and CEO, MyOwnMed, Inc

SzeKi Sim,
Head of Community & Brand, SGInnovate

Soo Khee Chee, MBBS, MD, FRACS, FACS, FAMS
Surgical Oncologist and Head Neck Surgeon, Head of Department of General Surgery, Singapore General Hospital; Founding Director, National Cancer Centre Singapore; Principal Investigator, National Research Foundation; Deputy CEO, Research and Education, SingHealth Duke-NUS Academic Medical Centre

Kasia Suzor,
Co-Founder and CEO, Ardion

Toh Han Chong, BSc, MB BCHIR, MRCP, FRCP, FAMS
Senior Consultant and Deputy Medical Director, National Cancer Centre Singapore; Associate Professor, Cancer & Stem Cell Biology Programme, Duke-NUS Medical School; Adjunct Principal Investigator, Singapore Immunology Network and Institute of Molecular and Cell Biology, A*STAR

Chrisicavin Wijaya
Children’s Cancer Foundation

Wong Tien Yin, MBBS, MMed(Ophth), PhD (John Hopkins), FAFPHM, FAMS, FRANZCO, FRCS(Ed), MPH Provost’s Chair Professor & Medical Director, Singapore National Eye Centre; Chairman, Singapore Eye Research Institute; Vice-Dean, Duke-NUS Medical School, National University of Singapore

Yeo Joo Guan, MBBS, PhD, MRCPCh (UK), MMEd (Paeds) (Singapore) Clinician-Scientist, Translational Immunology Institute, SingHealth Duke-NUS Academic Medical Centre; Assistant Professor, Duke-NUS Medical School Singapore; Consultant, Division of Medicine, KK’s Women’s and Children’s Hospital

Carolyn Lam Su Ping, MBBS, PhD, MS, FACC, FAMS, FESC, FRCP
Senior Consultant, National Heart Centre, Singapore (NHCS); Professor of Duke, National University of Singapore (NUS) Cardiovascular Academic Clinical Programme; Director, Clinical & Translational Research Office, NHCS; Director, Women’s Heart Clinic, NHCS; Scientific Advisor, Clinical Trials Coordinating Centre, SingHealth; Affiliate Member, SingHealth Duke-NUS Institute of Precision Medicine; Associate Editor, Circulation; Associate Editor, European Journal of Heart Failure

Lin Xiangqian,
Group President & CEO, Esco Group;
Managing Partner, Esco Ventures;
Co-Founder Carmenix, Maiden Therapeutics, Carmine Therapeutics

John C W Lim, MBBS, MSc, MP(M (Harvard), FAMS
Professor of Practice & Executive Director, Centre of Regulatory Excellence, Duke-NUS Medical School Core Lead (Policy), SingHealth Duke-NUS Global Health Institute;
Senior Advisor, Ministry of Health, Singapore; Chairman, Singapore Clinical Research Institute & National Health Innovation Centre

Fiona Loke Wei Ling, BS (EE), MS (EE)
Singapore-Stanford Biodesign Fellow 2011; Senior Manager, Medical Technology Office, SingHealth;
Co-Curriculum Head, Singapore Biodesign

Michael Howard Merson, MD
Director, SingHealth Duke-NUS Global Health Institute;
Wolfgang Joklik Professor of Global Health, Duke University

Steven Myint, MD, PhD
Chairman Karoo CGT

Ng Kee Chong, MBBS, MMEd(Paeds), FRCPH (UK)
Chairman Medical Board
Senior Associate Dean, KK Women’s and Children’s Hospital (KKH); Adjunct Associate Professor, Duke-NUS Medical School, Yong Loo Lin School of Medicine, National University of Singapore, Lee Kong Chian School of Medicine, National University of Singapore

Joanne Ngeow, MBBS, FRCP, MPH
Head, Cancer Genetics Service, Division of Medical Oncology, National Cancer Centre Singapore; Associate Professor, Lee Kong Chian School of Medicine, Nanyang Technological University

Vicki Seyfert-Margolis, PhD
Founder and CEO, MyOwnMed, Inc

SzeKi Sim,
Head of Community & Brand, SGInnovate
Organisers
EUREKA Institute for translational medicine
(www.eurekainstitute.org)
SingHealth Duke-NUS Academic Medical Centre
(https://www.academic-medicine.edu.sg)

Organising Committee
Salvatore Albani
Scott Compton

Course Coordination
Tanneke Zeeuw, +65 8168 6884
Benjamin Lim, +65 9730 9311

Evaluations
Scott Compton, Jean Xie Huijuan
(Duke-NUS Medical School)

Course Venue
NOVA Room
One°15 Marina Club
11 Cove Drive, Sentosa Cove, Singapore 098497
(http://one15marina.com)

How to get there
1. By One°15 Marina shuttle bus (see instruction provided in the following)
2. By Car (see instruction provided in the event confirmation letter which will be attached in notification email)
3. MUST bring along the event confirmation letter for free entry

By One°15 Marina shuttle bus
Show hardcopy or digital copy of the event confirmation letter to the driver for access.
1. Shuttle bus pick up point is from Harbourfront MRT Station Exit D taxi stand. Please see below schedule.
2. Upon alighting, turn right and walk along the brick pathway to the clubhouse.
3. Once entering the clubhouse, proceed to the lobby where there will be signs pointing you to the event’s venue.

Shuttle operating schedule to One°15 Marina
<table>
<thead>
<tr>
<th>Time</th>
<th>From Harbourfront MRT Station Exit D taxi stand (Mon-Fri)</th>
</tr>
</thead>
<tbody>
<tr>
<td>07:45</td>
<td></td>
</tr>
<tr>
<td>08:10</td>
<td></td>
</tr>
<tr>
<td>08:30</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Time</th>
<th>From One°15 Marina to Harbourfront MRT Station</th>
</tr>
</thead>
<tbody>
<tr>
<td>17:10</td>
<td>20:15</td>
</tr>
<tr>
<td>17:40</td>
<td>21:10</td>
</tr>
<tr>
<td>18:10</td>
<td>21:40</td>
</tr>
<tr>
<td>18:30</td>
<td>22:10</td>
</tr>
<tr>
<td>19:15</td>
<td>22:45</td>
</tr>
<tr>
<td>19:45</td>
<td>23:00</td>
</tr>
</tbody>
</table>

Important note:
Pre-arranged transport IN and OUT of One°15 Marina is provided at stipulated timings only. Kindly arrange your own transport at own cost, if you miss it.
Eureka Dynamic Sessions
A significant element of the programme is going to involve YOU talking, either one-to-one or in small groups. The aim of all these sessions is to help you to learn from each other and the faculty directly, and to focus on those parts of translation medicine, and a career in translational medicine, that matter most to you.

Unfolding Case Study – the magic bullet
Written by: Vicki Seyfert-Margolis

This case examines the full translational tightrope of a targeted therapy, from lead identification to Phase II and III clinical trials. You will work in depth with the case in a pre-allocated small-group setting over three separate sessions (Wednesday, Thursday and Friday).

Through this case, you’ll grapple with the development of a therapy intended for a targeted sub-population, and explore the issues arising in the post-market phase. In addition, you will discuss and determine research and business strategies necessary to "translate" a potential therapeutic and co-develop its companion biomarker. Parallel concepts of collaboration and team will also be explored.

Recommended Reading:

Mentoring
You will each present a dilemma you are currently facing to a small group of peers. You will be allocated to a group, which will be mentored by a faculty member. Your fellow course participants will act as a consultation group. The objective is to advance personal learning while practicing and improving approaches to, and organisation of, problem solving.

Reflections using practical real-world problems will anchor the concepts raised in the didactic portion of the programme.

As some of you already know, work with or have worked with some of the faculty members, every effort will be made to ensure you have “neutral” tutors guiding the sessions. In addition, unless otherwise specified and agreed to by the group, discussions in the mentoring session are treated as confidential.

You will have your first session on Thursday morning, then come back together on Friday morning.

Speed Dating
“Speed Dating” provides the opportunity for you to have a series of one-on-one discussions with individual faculty for 10 minutes each. Who you talk with and on what topics are your choices!

Please consult the faculty biographies in this booklet prior to completing the signup sheet, which will be prominently displayed and made available from Monday.

There will be two sessions: Tuesday afternoon and Friday morning.

Ideation & Design Thinking
Innovation requires creativity, inspiration and great ideas, but bringing great inventions into clinical practice also takes intense due diligence, rigorous technical development and clinical as well as commercial de-risking.

You will have the opportunity to try out the processes outlined in the first session on Monday during with team-based hands-on exercises on Monday, Tuesday and Thursday, with a final ‘Shark Tank’ on Friday afternoon.
Raising Your Communication Game

The Eureka Presentation Workshop

*Communication is not something you add on to science; it is the essence of science.*
- Alan Alda

Bad presentations are a contagion, spread by fear and lack of preparation. In this session, we discuss unusual and effective techniques for engaging in clear scientific communication, using techniques gleaned from the TED talks series, from the Alan Alda Center for Communicating Science at Stonybrook University, and the experience of our mentors and instructors. Goals of this interactive and experiential session are to raise each presenter’s speaking game, with improved audience awareness and focus, including a focus on tailoring communication style to the audience and predictable, high audience engagement.

In addition to a brief introductory session focused on general concepts of excellent scientific communication, this session will involve TED-talk type presentations by each participant in a small group setting. Each presentation will be recorded. After the presentation, the speaker will then review her/his own tape in private. During this time, the group will prepare constructive feedback for the presenter. Afterward, the group gets back together to hear the presenter’s own reflections and provide feedback intended to further raise that presenter’s game.

For those interested, tips on giving feedback are provided in the material for this session.

Feedback Tips

**Definition**
The process of giving data back to the participant for the purpose of bringing about change.

Feedback involves responding specifically to an event or occurrence, whether that event be good or bad. Positive and negative feedback should be distinguished from complimenting and criticising.

Evaluation is an assessment of a learner’s achievement and/or performance.

1. Feedback should be undertaken with the observer and participant working as allies with common goals. Begin by discussing respective expectations.
2. Feedback should be descriptive rather than evaluative.
3. Feedback should deal with specific events, rather than generalisations.
4. Feedback should be well-timed, and expected, in close proximity to the event, but not when – the recipient is post-call or angry about the issue; facts are missing; or both sides of the situation have not been explored.
5. Feedback should be based on first-hand data.
6. Feedback should be focused on behaviours that are amenable to change.
7. Feedback should involve sharing of information, rather than giving advice, leaving the receiver free to decide for themselves in accordance with their own goals and needs.
8. Feedback can be structured to include subjective data, as long as it is clearly labeled as such.
9. Feedback should be checked to insure clear communication by having the receiver try to rephrase the feedback.
10. Feedback should be followed by attention to the consequences of feedback.

**Taking the Plunge**
1. Be clear about the purpose of the feedback session.
2. Get the receiver’s perspective as to how things are going.
3. The sandwich technique (i.e., good / bad / good) isn’t always reliable.
4. Ask the recipient to offer solutions.
5. Develop solutions to the problem, and a plan to improve the situation.

Course Schedule
<table>
<thead>
<tr>
<th>Time</th>
<th>Title &amp; Speakers</th>
</tr>
</thead>
<tbody>
<tr>
<td>08:30-09:00</td>
<td>Registration</td>
</tr>
<tr>
<td>09:00-10:00</td>
<td>Introduction / Story of Your Name</td>
</tr>
<tr>
<td></td>
<td>Speakers: Soo Khee Chee / Scott Compton</td>
</tr>
<tr>
<td>10:00-10:15</td>
<td>Break</td>
</tr>
<tr>
<td>10:15-11:15</td>
<td>Patient Voices</td>
</tr>
<tr>
<td></td>
<td>Speakers: Toh Han Chong, Chriscavin Wijaya (Children’s Cancer Foundation)</td>
</tr>
<tr>
<td></td>
<td><strong>Abstract</strong></td>
</tr>
<tr>
<td></td>
<td>Childhood cancer survivors often go through different challenges in their cancer treatment journey. One of their challenges is coping with treatment and its side effects. This session will shed light on a childhood cancer survivor's journey with treatment and how it changed his life. It is important for medical professionals to understand how cancer treatment affects patients’ lives so that we can better support them through this journey.</td>
</tr>
<tr>
<td>11:15-12:15</td>
<td>Mapping Translational Medicine: Introduction to TM</td>
</tr>
<tr>
<td></td>
<td>Speaker: Salvatore Albani</td>
</tr>
<tr>
<td></td>
<td><strong>Abstract</strong></td>
</tr>
<tr>
<td></td>
<td>In this session, the objectives of the course and concepts of translational medicine will be introduced and defined, also by leveraging on personal experience.</td>
</tr>
<tr>
<td></td>
<td><strong>Learning Objectives</strong></td>
</tr>
<tr>
<td></td>
<td>1. Define the field of translational medicine</td>
</tr>
<tr>
<td></td>
<td>2. Analyse the components involved</td>
</tr>
<tr>
<td></td>
<td>3. Discuss the challenges of translational medicine</td>
</tr>
<tr>
<td>12:15-13:30</td>
<td>Lunch</td>
</tr>
<tr>
<td>13:30-15:00</td>
<td>Concept of Druggability</td>
</tr>
<tr>
<td></td>
<td>Speaker: Salvatore Albani</td>
</tr>
<tr>
<td></td>
<td><strong>Abstract</strong></td>
</tr>
<tr>
<td></td>
<td>This encounter will distill the common elements related to identifying, nurturing and developing an idea. The content will evolve from self biographic to more analytical and objective. Specifically, the concept of what makes a discovery attractive for translational developments, what it takes, with whom one associates, what objective parameters are considered by the various stakeholders will be defined.</td>
</tr>
<tr>
<td>Time</td>
<td>Title &amp; Speakers</td>
</tr>
<tr>
<td>------------</td>
<td>----------------------------------------</td>
</tr>
<tr>
<td>15:00-15:15</td>
<td>Break</td>
</tr>
<tr>
<td>15:15-16:45</td>
<td>Ideation &amp; Design Thinking</td>
</tr>
<tr>
<td></td>
<td>Speakers: Derrick Chan, Fiona Loke</td>
</tr>
</tbody>
</table>

**Abstract**
Innovation requires creativity, inspiration and great ideas, but bringing great inventions into clinical practice also takes intense due diligence, rigorous technical development and clinical as well as commercial de-risking. This session provides an overview of the medtech innovation process from unmet need to real-world solution, based on the proven Stanford Biodesign methodology. Participants will have the opportunity to try out the process with team-based hands-on exercises.

**Learning Objectives**
1. Gain an overview of the steps involved in the medtech innovation process
2. Understand how to identify and validate an unmet clinical need, ending with an appropriate need specification
3. Practise brainstorming addressing the need specification
4. Gain insights on the innovation journey through real-world case studies as a project group
5. Develop concepts and solutions to meet the unmet need and experience intellectual property, regulatory and commercial considerations
6. Present solutions to a panel and the class

**Preparation**
1. Web article on ebiodesign. Weblink is [http://ebiodesign.org](http://ebiodesign.org)
2. Article on Clinician Innovator (Attached in notification email)
3. Article on Needs-Based Innovation in Interventional Radiology - The Biodesign Process (Attached in notification email)

**Pre-Session Thought Questions for Participants**
1. What does clinical innovation mean to you?
2. What do you think makes a clinician innovator?

<table>
<thead>
<tr>
<th>Time</th>
<th>Title &amp; Speakers</th>
</tr>
</thead>
<tbody>
<tr>
<td>16:45-18:15</td>
<td>Overcoming Valley of Death</td>
</tr>
<tr>
<td></td>
<td>Speaker: Soo Khee Chee</td>
</tr>
</tbody>
</table>

**Abstract**
The research valley of death has been a real concern not just for individual researchers but, for governments, universities at medical institutions funding biomedical research. The basic challenge is that researchers, clinicians, pharma's and funders have different priorities and agenda. Research to be relevant and to be supported need to align with clinical needs and questions.

Suggestions and avenues will be discussed as to how we can overcome what is often the misalignment we see in the various partners in the research continuum.

**Learning Objectives**
Describe an idea / discovery and how to involve partners in the implementation

<table>
<thead>
<tr>
<th>Time</th>
<th>Title &amp; Speakers</th>
</tr>
</thead>
<tbody>
<tr>
<td>18:15-18:30</td>
<td>Gather at main lobby for transport to Town Restaurant</td>
</tr>
</tbody>
</table>

**18:45** Opening Dinner @ Town Restaurant
Address: Level 1, 1 Fullerton Square Singapore 049178
Tuesday, 19th November 2019

<table>
<thead>
<tr>
<th>Time</th>
<th>Title &amp; Speakers</th>
</tr>
</thead>
<tbody>
<tr>
<td>08:30-09:00</td>
<td><strong>Kick Off - Reflection on 18 Nov Session</strong></td>
</tr>
<tr>
<td>09:00-10:00</td>
<td><strong>Introduction: The Art of The Elevator Pitch, and more...</strong></td>
</tr>
<tr>
<td></td>
<td>Speaker: Gordon Baylis</td>
</tr>
</tbody>
</table>

**Abstract**
First impressions matter; style matters. But we have to take care that impression and style represent an accurate "thumbnail sketch" of the content. At the same time, the world is full of smart people with great ideas that deserve funding, so what is so special about you? Why should anyone pay attention to you? Remembering that we live in a world that is alleged to be "low attention span", the key is to make a rapid, initial impression, but one that encompasses "truth in advertising" and has staying power - that is causes those you interact with to want to devote time and attention to you and your ideas.

**Learning Objectives**
1. Introduce themselves
2. Give an effective "elevator pitch"
3. Find their uniqueness
4. Know how to begin
5. Stand out
6. Get enough attention that their ideas get a fair hearing

**Pre-Session Thought Questions for Participants**
1. What is my elevator pitch?
2. Who am I? What makes me special?
3. Why am I in this business

<table>
<thead>
<tr>
<th>10:00-10:15</th>
<th>Break</th>
</tr>
</thead>
<tbody>
<tr>
<td>10:15-11:15</td>
<td><strong>Drug Development Process</strong></td>
</tr>
<tr>
<td></td>
<td>Speaker: Vicki Seyfert-Margolis</td>
</tr>
</tbody>
</table>

**Abstract**
A critical component of translating ideas from the lab to the clinic is the design of a human clinical trial and post-market plan. The process for studying new interventions in humans and bringing them to market/clinic is complex and requires an understanding of the basic parameters surrounding clinical trial design, feasibility, execution, and regulatory and commercial considerations. This session will discuss considerations for the drug development product path using a case to illustrate the complexities and stakeholders that need to be considered when developing a new drug.

**Learning Objectives**
By the end of this session, participants will be able to identify core components of drug development and challenges associated with each of these core components.

| 11:15-12:15 | **Contemporary Clinical Trials I**                        |
|            | Speaker: Vicki Seyfert-Margolis                           |

**Abstract**
Developing a new medical product today not only means getting an approval from a regulatory agency. Increasingly the action for successful marketing of new medical products has shifted to the world post-approval. In this talk, we will explore pragmatic, basket, decentralised, real world trial designs and re-thinking clinical endpoints.
<table>
<thead>
<tr>
<th>Time</th>
<th>Title &amp; Speakers</th>
</tr>
</thead>
</table>
| 12:15-12:45  | **Contemporary Clinical Trials II**  
Speaker: Robert Kerle |
| Abstract     | Today's clinical trials present some familiar and a number of new challenges. Trials are increasing in complexity, target patient populations are more tightly defined and harder to find. In this talk we will focus on how to leverage on data, technology and novel concepts of risk based monitoring to meet some of these challenges in the design and management of clinical trials. |
| 12:45-14:00  | Lunch                                                |
| 14:00-15:00  | **Gender & Ethnicity Equipoise in Medicine**  
Speakers: Ann-Marie Chacko, Valerie Chew, Joanne Ngeow |
| Abstract     | In many countries, women and ethnic minorities face challenges in getting ahead with their career in medicine or research. Women or ethnic minorities are still grossly discriminated against in terms of earning lower salary, limited with opportunities for training, promotions or research funding and under-represented at senior leadership positions. Gender and ethnicity bias is still an on-going challenge we face in our society. This session aims to share experiences, views and opinions on the challenges we face and how to overcome such challenges with improvements we hope to achieve to tackle this issue. |
| Learning Objectives | 1. Understand and share the challenges in gender & ethnicity inequality in scientific/medicine research  
2. Identify and discuss ways on how this situation could be improved |
| Pre-Session Thought Questions for Participants | 1. Do you face inequality in your career based on gender or ethnicity?  
2. Do you have any suggestions on how to overcome the challenges? |
| 15:00-15:15  | Break                                                |
| 15:15-16:15  | **Speed Dating**  
See p.5 on Eureka Dynamic sessions for details |
| 16:15-17:15  | **Journey of a Translational Scientist**  
Speaker: Yeo Joo Guan |
| Abstract     | At the centre of Translational Medicine (TM) is the Translational Scientist whose critical role involves the continuum of activities from the conception of an idea to clinical testing for the ultimate goal of improving health and clinical outcome in diseases. This session will involve the sharing of experience from an early career Translational Scientist, both personal and those learnt from others, with the objective of closing the chasm across the valley of death for TM. Diverse issues such as mentorship, training needs, potential pitfalls, and work-life balance will be shared in the form of story-telling. |
| Learning objectives: | By the end of this session, participants will be able to reflect and identify personal pitfalls that may hinder their success to become a successful Translational Scientist. |
| 17:15-18:30  | **Design Challenge**  
See p.5 on Eureka Dynamic sessions for details |
**Wednesday, 20th November 2019**

<table>
<thead>
<tr>
<th>Time</th>
<th>Title &amp; Speakers</th>
</tr>
</thead>
<tbody>
<tr>
<td>08:30-09:00</td>
<td><strong>Kick Off - Reflection on Mentoring</strong></td>
</tr>
<tr>
<td>09:00-10:00</td>
<td><strong>Regulatory Aspects</strong>&lt;br&gt;Speaker: Vicki Seyfert-Margolis</td>
</tr>
</tbody>
</table>

**Abstract**
Translational medicine requires a thorough understanding of how regulatory agencies and considerations will impact the ability to move a product from concept to market and clinic. Premarket considerations are an important and essential part of the regulatory process for drug approval. However, post-market activities are becoming increasingly important for establishing how an innovative product should be used in typical care settings, not necessarily reflected in traditional randomised controlled trials. These aspects of defining real world benefit and effectiveness in addition to efficacy are critical for maximising a new drug’s benefit once in the clinic. This session will discuss the latest developments in patient-focused drug development, real world evidence studies, and how these novel clinical trial designs are increasingly being used to support regulatory submissions, clinical guidelines and commercialisation.

The regulatory landscape for clinical trials in paediatrics is substantially changed thanks to legislative initiative first in the United States and then in the European Union allowing an easier access especially to innovative drugs. This session will discuss the regulatory requirements and provide key examples from the paediatric field.

**Learning Objectives**
By the end of this session, participants will be able to:
1. Begin to think through study design considerations for real world evidence trials
2. Describe the difference in regulatory landscape in North America and Europe
3. Prepare a Paediatric Investigation Plan (PIP) or a Paediatric Study Plan (PSP)

| 10:00-10:30  | **Perspectives on Regional Regulatory Systems and Developments in the Asia Pacific**<br>Speaker: John Lim |

**Abstract**
Navigating national and regional regulatory systems is a key issue in successfully bringing new therapeutic products to the market to facilitate patient access. This aspect is not always adequately considered in strategic planning for development of new therapies. The session will describe key principles of good regulation, and provide an overview of developments in regulatory systems in South-East Asia and the Asia-Pacific, including the current emphasis on convergence advocated by APEC and the WHO.

| 10:30-10:45  | **Break** |

<table>
<thead>
<tr>
<th>Time</th>
<th>Title &amp; Speakers</th>
<th>Abstract</th>
<th>Learning objectives:</th>
<th>Preparation</th>
<th>Pre-Session Thought Questions for Participants</th>
</tr>
</thead>
<tbody>
<tr>
<td>10:45-11:15</td>
<td><strong>Building A Paediatric Academic Research Enterprise : The Singapore Perspective</strong>&lt;br&gt;Speaker: Ng Kee Chong</td>
<td><strong>Abstract</strong>&lt;br&gt;KK Women's &amp; Children's Hospital is the largest tertiary centre for obstetrics, gynaecology and paediatrics in Singapore. It is part of the Singhealth Academic Medicine Cluster – the largest of the 3 public health care clusters in Singapore serving the needs of up to 50% of the Singapore population. The Singhealth Duke-NUS Academic Clinical Programs (ACPs) for paediatrics and O&amp;G is an initiative under Singhealth Duke-NUS to integrate and drive research and education for paediatrics and O&amp;G. We share our academic journey to develop and build a sustainable O&amp;G and paediatric academic research enterprise for Singapore, regionally and internationally, leveraging on Singapore’s exemplary cosmopolitan East-West connectivity. This session will discuss the challenges and possible solutions to ensure our journey continues on its forward trajectory to establish ourselves as a key node in the international consortium of O&amp;G and paediatric academic research.</td>
<td><strong>By the end of this session, participants will be able to:</strong>&lt;br&gt;1. Understand how Singhealth is building its academic research enterprise for clinical care&lt;br&gt;2. Understand the challenges and suggest solutions and strategies moving forward to mitigate these challenges</td>
<td><strong>Preparation</strong>&lt;br&gt;Reading assignments – Sung NS, Crowley WF, Jr, Genel M, et al. Central Challenges Facing the National Clinical Research Enterprise. JAMA. 2003;289(10):1278-1287 (doi:10.1001/jama.289.10.1278) (Attached in notification email)</td>
<td>1. What are the barriers and challenges of doing O&amp;G and paediatric academic research in Singapore?&lt;br&gt;2. How can we mitigate and overcome these barriers and challenges?</td>
</tr>
<tr>
<td>11:15-11:45</td>
<td><strong>International Networks</strong>&lt;br&gt;Speaker: Chong Yap Seng</td>
<td><strong>Abstract</strong>&lt;br&gt;Building international networks for the purpose of medical research is important, especially if the disease of interest is relatively rare or if large patient populations are required. However, cross-border research is plagued by many issues, not the least of which are commitment, competency, funding, logistical and regulatory in nature. Using an example based on a tuberculosis research program in Asia, we will study some of the approaches used to set up research networks and the issues faced.</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>11:45-12:45</td>
<td><strong>Building a Deep Tech Ecosystem</strong>&lt;br&gt;Speaker: SzeKi Sim</td>
<td><strong>Abstract</strong>&lt;br&gt;From climate change, to ageing population and urbanisation, the world has difficult challenges that we believe, can be tackled with Deep Tech – which we define as technology that has scientific research at its core, and one that is not easily replicable. In recent years, Singapore’s Deep Tech ecosystem has seen immense growth and interest, with Venture Capitalists (VC), talent, corporate and government partners working with scientists and researchers to build companies focusing in areas such as Artificial Intelligence, Autonomous Tech, Med Tech and more. In this presentation, SzeKi Sim, Head of Community and Brand at SGInnovate – a Singapore Government-backed VC and Deep Tech startups builder – will be sharing about the broad innovation landscape, as well as the key ingredients to build a robust and self-sustaining Deep Tech ecosystem here.</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>12:45-13:45</td>
<td>Lunch</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
### Time | Title & Speakers
---|---
13:45-15:15 | **Unfolding Case Study I: Magic Bullet**  
See p.5 on Eureka Dynamic sessions for details
15:15-15:30 | Break
15:30-16:30 | **Career as a Clinician Scientist: 20 years as a Clinician-Scientist and Innovator in Singapore: Pearls, Set-backs and Lessons**  
Speaker: Wong Tien Yin

**Abstract**  
The process of scientific discovery to clinical application is known is translational medicine, and can be defined as a focused, purposeful method to apply knowledge gained from scientific research to clinical practice. Translational medicine involves the pursuit of the patient’s health as the ultimate outcome. Unfortunately, translational medicine and the underlying innovation that drives it does not occur by chance and is in fact rare in normal healthcare settings. Translational medicine is long, tortuous, difficult and many scientific discoveries do not actually get to the patient or impact on care.

Clinician-scientists (CS) and clinician innovators (CI) are the foundations for translational medicine. CS/CI are physicians who understand both science/innovation and medicine, who are “connectors” between scientists, engineers and doctors, and who can speak multiple “languages”. Singapore has identified the development and support of CS/CI as being critical for the growth and success of the multi-billion dollar investment in biomedical research and for the transformation of our healthcare. Over the past two decades, there have been substantial improvement in the support and career development of CS/CI in Singapore, and a vibrant, exciting ecosystem has evolved. However, much more needs to be done to grow and sustain the pipeline of young CS, who must be identified, trained, mentored and supported throughout a long career of uncertainty and new challenges in the healthcare system

**Learning Objectives**  
By the end of this session, participants will be able to:
1. Understand the concept and importance of clinician-scientists in the healthcare system
2. Understand the challenges of being a clinician scientist and innovator

**Preparation**  
1. Articles on Clinician Scientist (Attached in notification email)

**Pre-Session Thought Questions for Participants**  
1. Why do you want to be CS/CI? What drives you?
2. Who are your role models?
3. What does success look like?

16:30-17:30 | **Keynote Encounter**  
**Global Health: What is in our Future?**  
Speaker: Michael H. Merson

**Abstract**  
We live in an increasingly connected world that is rapidly changing with growing and aging populations, emerging and re-emerging infectious diseases, higher rates of chronic diseases, threats from climate change, fluctuating socio-political dynamics and advances in health care. This landscape presents many challenges as well as opportunities for addressing global health priorities now and in the future.

**Learning Objectives**  
1. Describe current and future challenges in global health
2. Understand the importance of global health priorities

**Pre-Session Thought Questions for Participants**  
1. How has global health changed over the past few decades and why is this important in addressing health in the future?
2. How does your research fit into the future priorities for global health?

17:30 | **Networking over Wine & Cheese @ Boaters’ Bar (On-Site)**
Thursday, 21st November 2019

<table>
<thead>
<tr>
<th>Time</th>
<th>Title &amp; Speakers</th>
</tr>
</thead>
<tbody>
<tr>
<td>08:30-09:00</td>
<td><strong>Kick Off - Reflection on Team</strong></td>
</tr>
<tr>
<td>09:00-10:00</td>
<td><strong>Mentoring Session I</strong></td>
</tr>
<tr>
<td></td>
<td>See p.5 on Eureka Dynamic sessions for details</td>
</tr>
<tr>
<td>10:00-10:15</td>
<td>Break</td>
</tr>
<tr>
<td>10:15-10:45</td>
<td><strong>High dimensionality and biomarkers in Translational Discovery: Applications to Myeloid Cells</strong></td>
</tr>
<tr>
<td></td>
<td>Speaker: Florent Ginhoux</td>
</tr>
</tbody>
</table>

**Abstract**

Dendritic cells (DCs), monocytes and macrophages play crucial and distinct roles in tissue homeostasis and immunity, but also contribute to a broad spectrum of pathologies and are thus attractive therapeutic targets. Potential intervention strategies aiming at manipulation of these cells will require in-depth insights of their origins and the mechanisms that govern their homeostasis. The focus of the laboratory is to understand the ontogeny of DCs, monocytes and macrophages, their differentiation pathways and how their unique ontogeny dictates their immune functions. Our approach encompasses the integration of high dimensional platforms such as RNAseq, single cell transcriptome analysis using microfluidic RNA sequencing and deep immunophenotypic assessment using state of the art 18 parameters flow cytometry or Cytometry by Time-Of-Flight mass spectrometry (CyTOF). Such high density molecular profiling at the single level and at unprecedented dimensionality and complexity will provide new insights in the biology of DC, monocyte and macrophage cell populations. Defining macrophage and DC populations on the criteria of their origin may aid our understanding of their discrete roles in tissue immunity and homeostasis, as ontogeny of DC and macrophage subsets likely underlie their functional specialisation.

**Learning Objectives**

By the end of this session, participants will be able to:
1. Understand new high dimensional approaches to characterise immune cells
2. Understand the heterogeneity of the myeloid cell system
Thursday, 21st November 2019

10:45-11:15  Speaking Other People’s Language
Speaker: Gianfranco Grompone

Abstract
Communication to non-scientists, i.e. attorneys, journalists, potential investors, industry partners, is a key step in Translational Medicine (TM). Very often, when new data and discoveries show significant scientific relevance to fulfill unmet medical needs, either at the in vitro or preclinical level, exploring and confirming their translational potential by requesting non-scientists’ opinion and often actions, is crucial. This communication process requires stepping out from the lab and its comfort zone to a new environment defined by non-scientific criteria, namely market potential, patentability, social and economic impact, industrial reproducibility, among others. Mastering communication is then crucial in this process. In this session, we will explore tools and tips to develop specific skills and assets which might help TM scientists in their careers. We will focus on 2 concrete case examples which will support the relevance of speaking other’s people language: 1) moving from Academia to Industry and 2) bringing science to a large public audience in a radio broadcasting context. We will navigate the delicate balance between accurately describing the results to non-experts without “betraying” the science behind the data. Communicating to non-peers is a great opportunity for a translational scientist to “unlearn”, to embrace adaptive challenges, to generate novel insights and to explore how to alleviate stress and anxiety during the whole exercise by stimulating empathy and facilitating multi-disciplinary and multi-cultural collaboration. But most importantly, this process should allow scientists and non-scientists working together and have fun.

Learning Objectives
By the end of this session, participants will be able to:
1. Reflect on the concept of vulnerability when stepping out of their comfort zone
2. Translate their work to non-peers, large public and non-expert stakeholders for a specific purpose
3. Evaluate, create and define their own communication style
4. Provoke and maintain curiosity in the audience by engaging creativity

Preparation
Look for information about the mythological Tower of Babel in Babylonia

Pre-Session Thought Questions for Participants
1. Explain your research topic to your grandmother/grandfather, or to a 5 years-old child
2. Make a list of the scientific terms and phrasings which are part of your day-to-day life
3. Look for clinical studies and/or scientific articles press releases in the media
11:15-12:15  **Intellectual Property**  
Speaker: Wainwright Fishburn

**Abstract**
In a life sciences start-up, Intellectual Property (IP) is one of the key pillars that support the fledgling company and contribute to its value. There are different kinds of IP that provide different kinds of protection and allow the ‘owner’ to exert certain rights against unlicensed users. In this session, we will consider IP broadly, and examine how legal rights are used to protect IP in a life sciences start-up company.

**Learning Objectives**
1. By the end of this session, participants will be able to:
2. Identify the different kinds of Intellectual Property (IP) and distinguish between IP and IP rights
3. Describe what is necessary for a proposed ‘invention’ to be patentable
4. Distinguish between an inventor and an author
5. Determine how to adequately protect inventions in a life sciences’ start-up
6. Understand how IP rights can be used to provide legal protection

**Preparation (Prior Reading)**
2. Slides setting out Case Studies that identify different business scenarios

**Pre-Session Thought Questions for Participants**
1. What kind of protection would I want for the product that I want to make and commercialise?
2. How can I ensure that:
   A. I have the protection that investors see as necessary?
   B. I have the breadth of protection required (comprehensive protection, which could also include TM, copyright)?
   C. My IP is positioned to facilitate future protection?

12:15-13:30  **Lunch**

13:30-15:00  **Unfolding Case Study II: Magic Bullet**  
See p.5 on Eureka Dynamic sessions for details

15:00-15:15  **Break**

15:15-17:15  **Presentation Workshop**  
See p.6 on Presentation Workshop session for details

17:15-18:30  **Design Challenge**  
See p.5 on Eureka Dynamic sessions for details
# Friday, 22nd November 2019

<table>
<thead>
<tr>
<th>Time</th>
<th>Title &amp; Speakers</th>
</tr>
</thead>
<tbody>
<tr>
<td>08:30-09:00</td>
<td><strong>Kick Off - Reflection</strong></td>
</tr>
<tr>
<td>09:00-10:00</td>
<td><strong>Mentoring Session II</strong>&lt;br&gt;See p.5 on Eureka Dynamic sessions for details</td>
</tr>
<tr>
<td>10:00-10:15</td>
<td><strong>Break</strong></td>
</tr>
<tr>
<td>10:15-11:15</td>
<td><strong>Speed Dating</strong>&lt;br&gt;See p.5 on Eureka Dynamic sessions for details</td>
</tr>
<tr>
<td>11:15-12:00</td>
<td><strong>Work Life Balance: An Elusive Dream</strong>&lt;br&gt;Speaker: Carolyn Lam</td>
</tr>
<tr>
<td></td>
<td><strong>Abstract</strong>&lt;br&gt;With physician burnout being a common topic today, many are pointing toward improving work-life balance. However is this an elusive dream for doctors? One study of physicians undergoing training was aptly titled, &quot;You can't be a person and a doctor.&quot;, and cited female physician trainees as appearing to be more burdened by the lack of work-life balance. This talk will explore the dream of work-life balance from the perspective of a female clinician scientist in Singapore, and consider strategies from personal experience that may apply regardless of gender or degree.</td>
</tr>
<tr>
<td></td>
<td><strong>Learning Objectives</strong>&lt;br&gt;1. Evaluate personal life goals&lt;br&gt;2. Consider personal strategies to achieve work-life balance</td>
</tr>
<tr>
<td></td>
<td><strong>Pre-Session Thought Questions for Participants</strong>&lt;br&gt;1. What does work-life balance mean to you?&lt;br&gt;2. What is your life's goal?</td>
</tr>
<tr>
<td>12:00-13:15</td>
<td><strong>Lunch</strong></td>
</tr>
<tr>
<td>13:15-14:15</td>
<td><strong>Unfolding Case Study III: Magic Bullet</strong>&lt;br&gt;See p.5 on Eureka Dynamic sessions for details</td>
</tr>
<tr>
<td>14:15-14:45</td>
<td><strong>Transition from Academia to Business</strong>&lt;br&gt;Speaker: Steven Myint</td>
</tr>
<tr>
<td></td>
<td><strong>Abstract</strong>&lt;br&gt;The transition from academia to business can involve much consideration. To be successful it requires planning and recognition of change in both mindset. This session will be a review of how the speaker did it but be open to questions that attendees also have.</td>
</tr>
<tr>
<td></td>
<td><strong>Learning Objectives</strong>&lt;br&gt;1. Have an understanding of what considerations to make if wanting to make a transition&lt;br&gt;2. To have a template of what the options should be and what would suit different types</td>
</tr>
<tr>
<td></td>
<td><strong>Pre-Session Thought Questions for Participants</strong>&lt;br&gt;1. What do you want to achieve in life?&lt;br&gt;2. Why do you want to do translational medicine rather than basic science?&lt;br&gt;3. Do you know what industry options are available?</td>
</tr>
</tbody>
</table>
### Friday, 22nd November 2019

<table>
<thead>
<tr>
<th>Time</th>
<th>Title &amp; Speakers</th>
</tr>
</thead>
</table>
| 14:45-15:30   | **Starting a Company**  
Speaker: Kasia Suzor                                                                 |
| **Abstract**  | The spirit of life science entrepreneurship is alive and well, with outstanding  
innovation hubs arising throughout the world. Of note, many of these hubs flourish  
in close proximity to research universities. If universities are the engine for  
discovery, then startups are the vehicle for innovation. This session will discuss  
what it takes to start a company with the main components of building your key asset -  
the team, marketing strategy, intellectual property strategy, portfolio management,  
strategic alliances and funding options.                                      |
| **Learning Objectives** | Understand the logistics and dynamics of starting up a company, key area to focus on. Be aware of what are the essential pieces to the biotech startup puzzle. |
| 15:30-15:45   | **Break**                                                                        |
| 15:45-16:30   | **Science Substrate for Enabling Life Science Company Creation: Current Trends**  
Speaker: Lin Xiangqian                                                       |
| **Abstract**  | Many investigators aim to realise real-world impact of their research via spin-off's  
and new ventures. However, there is a subset of research outcomes which are  
commercially attractive as the basis for new company creation. Another subset may  
be more appropriately commercialised via a license to an established company.  
Others may struggle to attract any subsequent commercialisation deals at all. What  
are current trends in relation to “venture-worthy” science substrate for new company  
formation? How can investigators better skew their research focus to generating such  
science substrate — to increase their odds of spin-off's and new company formation? |
| **Learning Objectives** | 1. Understand current trends in new life science company formation  
2. Visualise the “phenotype” of research outcomes, which is relevant science-substrate for new company creation in today’s market  
3. Distinguish between what is relevant for new company formation versus a license to an established company  
4. Understand how to skew their research focus to increase the odds of generating spin-off’s and attracting venture capital investment |
| **Preparation** | Report on Silicon Valley Bank: Healthcare investments and exits  
| **Pre-Session Thought Questions for Participants** | 1. What is my current research focus and likely research outcomes?  
2. Is there new company formation around research in my space? |
| 16:30-18:00   | **Design Challenge: Shark Tank**  
See p.5 on Eureka Dynamic sessions for details |
| 18:00         | **Closing Dinner: BBQ @ One15Marina**                                           |
ABOUT SINGAPORE

Though physically small, Singapore is an economic giant. It has been Southeast Asia's most modern city for over a century. The city blends Malay, Chinese, Arab, Indian and English cultures and religions. Its unique ethnic tapestry affords visitors a wide array of sightseeing and culinary opportunities from which to choose. A full calendar of traditional festivals and holidays celebrated throughout the year adds to its cultural appeal. In addition, Singapore offers luxury hotels, delectable cuisine and great shopping! The island nation of the Republic of Singapore lies one degree north of the Equator in Southern Asia. The country includes the island of Singapore and 58 or so smaller islands. Because of its efficient and determined government, Singapore has become a flourishing country that excels in trade and tourism and is a model to developing nations. The capital city, also called Singapore, covers about a third of the area of the main island.

Located at the tip of the Malay Peninsula, Singapore's tropical climate welcomes both leisure and business travellers year round. The island republic's excellent infrastructure enables visitors to enjoy its many sites and attractions in a safe, clean and green environment. Award winning Changi Airport provides airlinks to major cities around the world. The train and subway systems are clean, fast and efficient. In addition, its state-of-the-art cruise terminal has established Singapore as one of the premier cruising centre of South East Asia and an exciting port of call on any Asian cruise itinerary.

In the city, there is no need for a car. Public transportation is excellent and walking is a good way to explore the city. All major attractions are also accessible by tour bus. Since the city is only 60 miles (100k) from the equator, the tropical temperatures do not vary much. Rainfall is fairly evenly distributed through the year. No matter when you choose to visit, warm weather will be abundantly available. The visitor is struck immediately by Singapore's abundance of parks, nature reserves, and lush, tropical greenery.

Singapore's progress over the past three decades has been remarkable, yet the island has not been overwhelmed by development. Visitors will discover a wealth of historical treasures from the past, in the beauty of older buildings, values and traditions that have survived in the face of profound social and geographical change.

Faculty Biographies
Salvatore Albani, MD, PhD

Salvatore Albani, is an internationally renowned rheumatologist and immunologist. He is a Professor at Duke-NUS Medical School Singapore and Director of the Translational Immunology Institute at SingHealth-Duke-NUS Academic Medical Centre.

Before joining Duke-NUS, Dr. Albani served as Director of the Translational Medicine Unit at the Clinical Investigation Institute at the University of California, San Diego, where he also was Professor of Medicine and Pediatrics. His fundamental research interest is in understanding human immunity and contributing the knowledge to therapeutic and diagnostic advancements. He has developed several innovative approaches in the area of induction and maintenance of immune tolerance in humans, being responsible for the whole translational process from idea to the conclusion of a Phase II clinical trial in autoimmune inflammatory diseases, which have a large impact on society and individuals.

He has been responsible for conception and execution of each of the stages of this complex itinerary, which spans a wide and diverse gradient of technologies and challenges. These include molecular immunology, lead identification and validation, intellectual property, CMC (Chemistry, Manufacturing and Controls), IND (Investigational New Drug filings), trial design, data management and analysis, interfacing with Venture Capital and Pharma, leading complex groups in a multi-center setting, etc. The technology platform has applications in diseases that could benefit from a restoration of immune tolerance. This translational research itinerary has been the original backbone of his career, and witnessed by a rich publication trail (among others Nature Medicine, Lancet, JCI, PNAS, Nature Rheumatology, A&RD, etc, H factor 40) and by approximately 100 patents. Development of high throughput technology platforms is also part of his scientific career. These platforms aim to provide tools for knowledge-based diagnostic and therapeutic decisions.

In his role as an educator, it has been his privilege to mentor many talented individuals, and to provide the right challenges and learning opportunities to help them grow and advance. He seeks to expand this even further by helping to create and nurture the next generation of translational scientists. An important step is cultivating in translational professionals the necessary awareness, knowledge and experience to contribute significantly to the advancement of the field.

Scott Compton, PhD

Scott Compton is the Course Director of the Merlion School, and also an Associate Professor and Associate Dean of Medical Education at the Duke-NUS Medical School. He also serves as the Deputy Director of the newly established Prehospital Emergency Research Center at Duke-NUS. He earned his PhD from Wayne State University (USA) in Educational Evaluation & Research, where he was mentored by one of the world’s leading educational statisticians, Shlomo Sawilowsky, PhD, Professor & Distinguished Faculty Fellow of Educational Statistics. In his career, Dr. Compton has focused his research efforts on prehospital emergency care, palliative emergency medicine, and medical education. He has published over 60 peer-reviewed research papers and presented at over 100 international scientific meetings.

Additionally, he has served as a medical school accreditation reviewer and as an expert reviewer for the National Institutes of Health (USA), the Ministry of Education (Singapore), and as a member of the Editorial Boards of three academic journals. As a teacher, he has received teaching awards at every level of the educational spectrum, from elementary schools through graduate schools, and has mentored over 100 Emergency Medicine residents, medical students, faculty members, and post-doctoral fellows.
Gordon C. Baylis, DVM, DPhil

Gordon C. Baylis, DVM, DPhil, is a cognitive neuroscientist with interests in the effects of brain damage on cognitive and motor functions, and how recovery from brain damage can be maximised. He is currently serving as Associate Provost for Research at UAE University.

Prior to his arrival in UAE, Gordon Baylis has more than fifteen years experience in research administration – especially biomedical research – in addition to extensive experience in teaching and research in the area of brain function. His fundamental interest is on the neural basis of cognitive function, or how the brain “runs” the mind, and how this can be compromised by damage or dysfunction of the brain. He has used high-field MRI to understand brain function, and brain damage, and to track how recovery of function can occur in damaged brains. More recently, his interest includes the functions of consciousness, and how the brain constructs our sense of consciousness, and our sense of self-agency. These two cognitive functions are crucial to our sense of being human, and our well-being.

Gordon Baylis was previously Vice President for Research at Western Kentucky University where he led research administration and technology-based economic development. The Center for Research and Development was cited by the Commonwealth of Kentucky for excellence in technology-based economic development.

At the University of South Carolina, Dr. Baylis was involved for many years with building translational research centers across multiple universities and healthcare systems in the state under the state Centers of Economic Excellence initiative. This work entailed building public-private partnerships to facilitate translational research, especially in biomedicine, by raising funds to build research infrastructure and fund endowed professorships. Dr. Baylis coordinated the recruitment of endowed professors, as well as a program to hire interdisciplinary clusters of faculty, and a program to hire large numbers of research faculty on grant funding.

Dr. Baylis is passionate in his belief that the pursuit of knowledge and its application to challenges in the world is the most exciting career imaginable. Moreover, he believes that sustainable systems of wealth creation increasingly require the support of twin pillars of research universities and academic medical centers driving translational research. He has been married to his wife Leslie for thirty years, and has two adult daughters; he loves theatre and movies, and is an avid road cyclist.

Ann-Marie Chacko, PhD

As an Assistant Professor in the Duke-NUS Programme in Cancer and Stem Cell Biology, and Head of the Duke-NUS Laboratory for Translational and Molecular Imaging (LTMI), Prof Ann-Marie Chacko work to combine molecular imaging efforts in drug discovery and early drug development. Through academic and industrial collaborations through Duke-NUS’ world-class research programs, she lead the translational efforts for a portfolio of in vivo PET, SPECT, CT and optical imaging agents that span key therapeutic areas including oncology, immunology, infectious disease and neurobiology.

She currently leads a national initiative, the Cancer ImmunoTherapy Imaging (CITI) Programme, which received a S$22M Singapore Health and Biomedical Sciences (HBMS) Industry Alignment Fund Pre-Positioning (IAF-PP) grant in late 2018. This initiative aims to address the urgent call for biomarker-driven approaches to monitor tumour immune responses, leveraging on the expertise of its strong multidisciplinary team across 12 research organisations in Singapore and four research themes: Immunology, Chemistry, Imaging, and Clinical Trials.

To address some of the unique challenges faced by women scientists, Prof Chacko leads the SingHealth Duke-NUS Women in Science (WinS) Research Scientists Initiative to support the career development of female research scientists across all professional and training levels. Her flag-ship effort is the Career Advancement Programme (WinS-CAP) for early career scientists, providing in-depth training workshops, and faculty-peer mentor sessions.
Derrick Chan is Senior Consultant and Head of Paediatric Neurology at KK Women’s and Children’s Hospital, Singapore. He received his medical degree from Nottingham University, U.K., and a Masters in Clinical Investigation in NUS, Singapore. He trained in Great Ormond Street Hospital and the Royal Children’s Hospital in Melbourne in paediatric neurology and EEG and a Paediatric Epilepsy Fellowship at the Hospital for Sick Children in Toronto, Canada.

He set up the paediatric comprehensive epilepsy programme for the systematic evidence-based evaluation, investigation and management of children with seizures, including epilepsy surgery, the ketogenic diet and vagus nerve stimulator at KKH. He has published on the epidemiology of seizures and epilepsy in children and pediatric electroencephalography in epilepsy. He set up, led and published a study on the relationship of HLA*B1502 alleles with carbamazepine in severe cutaneous drug reactions in the Singapore paediatric population. His research interests include the epidemiology and pharmacotherapy of epilepsy, neurophysiology and applications of advanced technology in clinical practice for paediatric epilepsy.

Dr. Chew graduated with a PhD in immunology from Agency of Science, Technology and Research (A*STAR) Graduate Scholarship program in Singapore. Dr Chew then started her postdoctoral training in Singapore Immunology Network (SIgN), A*STAR focusing on tumour immunology. Since 2015, Dr Chew joined Translational Immunology Institute (TII), SingHealth Duke-NUS to advance her professional career in tumour immunology research. She also holds assistant professor position with Duke-NUS Medical School.

Dr Chew is the key researcher leading the project on understanding the impact of tumour immune microenvironment on clinical outcome in patients with hepatocellular carcinoma (HCC). Her work has gained recognition with multiple grant awards and high impact journals including Gut, Journal of the National Cancer Institute, Nature Genetics, and Journal of Hepatology.

Professor Chong Yap Seng is the Dean of Yong Loo Lin School of Medicine, National University of Singapore since 1 January 2019 and the Executive Director of the Singapore Institute for Clinical Sciences, Agency for Science, Technology and Research (A*STAR). He is also the Lead Principal Investigator of the National Research Foundation Translational and Clinical Research Flagship Programme on Developmental Origins of Health and Disease, and the founding Director of the A*STAR-NUS Singapore Centre for Nutritional Sciences, Metabolic Diseases, and Human Development. He is a senior consultant in the Department of Obstetrics & Gynaecology, National University Health System (NUHS) and a respected clinician and researcher in the field of women’s health and early development.

His other research interests include strategies to promote breastfeeding, the genetic epidemiology of pregnancy-related disorders, and intrapartum and postpartum management issues. He has over 300 research publications, including papers in the The Lancet, JAMA, and BMJ, and received more than $100 million in research grant funding. He also has numerous collaborations with industry, particularly in the area of early human development and nutrition. He was awarded the National Outstanding Clinician Scientist Award by the Ministry of Health in 2017.
Wainwright Fishburn, Jr., a prominent venture capital lawyer, is the Global Chair of Cooley’s Digital Health group.

As a recognised digital thought-leader, Wain is a frequent speaker at programs addressing industry issues, including at the International CES Digital Health Summit, USC’s Body Computing Conference, Impact Forum and the Samsung: Health + Tech Conference. Wain has also served as the Chair of the BIO Digital Health Forum at the BIO International Convention from 2014 – 2019.

As both a founder and counsel, Wain has worked with venture capital–backed companies across a variety of fields. For example, he works with groups that deploy high performance digital technology ranging from genomic research to applications in clinical medicine. He is Vice–Chairman of the Critical Path Institute, a public–private partnership created in part by the FDA, dedicated to integrating scientific advances into the development pathway. Mr. Fishburn has been recognised as a leading attorney in numerous publications, including among others, recognition by The Daily Journal as one of California’s top attorneys and was named by Nature as instrumental to the success of San Diego as a life science cluster.

As a community leader, he is past Chairman of the Sanford Burnham Prebys Medical Discovery Institute, one of the nation’s leading independent research institutes. He is a member of the Executive Committee of the UCSD Moores Cancer Center where he is afforded a clinical perspective on the application of breakthroughs in genomic medicine and is assisting with the Center for Personalised Cancer Therapy. He is a founding director of both the Corporate Directors Forum and BIOCOM, representing more than 1100 members life science companies and is a member of its Executive Committee. He also served on the board of The Bishop’s School in La Jolla, California.

Wain is a co–founder of seven companies, including two public companies. He is a third–generation Arizonan and earned his B.A. from the University of Arizona where he served on the Advisory Board for Tech Launch Arizona. He completed post–graduate work in human sciences as a Senior Fellow at the Australian National University and received his JD degree from the University of California, Hastings College of the Law where he served as President of the Hastings Board of Governors.

Wain is married with two young adult children. He is an avid traveller and cyclist, where most years he rides from San Francisco to San Diego with the Challenged Athletes Foundation. He has cycled Tour de France routes in France and rode 600 miles around the Cape of South Africa.

Florent Ginhoux graduated in Biochemistry from the University Pierre et Marie CURIE, Paris VI and obtained a Masters degree in Advanced Studies in Immunology from the Pasteur Institute, Paris. He then started his PhD in the Immunology Team of GENETHON, Evry and obtained his PhD in 2004 from the University Pierre et Marie CURIE, Paris VI.

As a postdoctoral fellow, Florent Ginhoux joined the Laboratory of Miriam Merad in the Mount Sinai School of Medicine (MSSM), New York where he studied the ontogeny and the homeostasis of cutaneous dendritic cell populations, with a strong focus on Langerhans cells. In 2008, he became an Assistant Professor in the Department of Gene and Cell Medicine, MSSM and member of the Immunology Institute of MSSM. He joined the Singapore Immunology Network (SIgN), A*STAR in May 2009 as a Principal Investigator. He joined the EMBO Young Investigator (YIP) program in 2013 and is a Web of Science Highly Cited Researcher in 2016 and 2017. He is also an Adjunct Visiting Associate Professor in the Shanghai Immunology Institute, Jiao Tong University, in Shanghai, China since 2015. Both laboratories are focusing on the ontogeny and differentiation of macrophages and dendritic cells (DCs).
Dr. Gianfranco Grompone is a senior scientist and team manager delivering high impact product solutions in a competitive global market by combining strong academic basic science background to industrial experience. Dr Grompone’s research interests include: microbiome and probiotics, nutrition and health, functional foods, prebiotics and symbiotics, microbiome-driven products and innovation, personalised nutrition, translational medicine and biotechnology. To date, he has developed solid networks and public-private partnerships worldwide, with a special focus in Latin America. He has been involved in science & technology prospective policies and innovation strategies in Latin American countries as a consultant. He has recently developed a science popularisation national radio broadcasting program in Uruguay, with a strong focus on microbiome related topics. He is a member of the Harvard Kennedy School Executive Education Alumni network.

Dr. Grompone got his agronomic engineer diploma at ENSAR (Ecole Nationale Supérieure Agronomique de Rennes, France) in 1999. After his PhD (1999-2002) at Pr. Dusko Ehrlich’s lab (INRA Jouy en Josas, France) where he focused on the role of homologous recombination in the replication of the chromosome of *E. coli*, he worked as a postdoc (2002-2005) at Pr. Philippe Sansonetti’s lab (Institut Pasteur, Paris, France), focusing on the early step of *Shigella flexneri* entry into intestinal epithelial cells. He then moved to Danone Research (Palaiseau, France) where he worked within the R&D Department for 10 years (2005-2015), focusing on the selection, functional characterisation, preclinical validation and clinical development of new probiotic strains for the dairy division. From 2014 to 2016 he directed the microbiome program at Bioaster, a new public-private Technology Research Institute co-founded by Danone Research, Institut Mérieux, Sanofi Pasteur, CNRS, INSERM, CEA, Institut Pasteur and Lyonbiopôle. He was the head of the biobusiness and IP direction at National Institute of Agronomic Research in Uruguay from 2016 to 2018. Since May 2018, he joined Lesaffre International R&D Corporate team in Lille, France to work as a Discovery Nutrition and Health Science leader with high focus on microbiome driven new products and bioactive molecules screening.

Robert Kerle is currently the head of research & Development Solutions in IQVIA, leading the Clinical Operations team across seven countries in Southeast Asia and Pakistan. He is also the Head of Prime & Partner Sites Initiative in Southeast Asia.

He previously managed the IQVIA commercial & market research business in Singapore and led the Clinical Planning & Analytics Services across Asia Pacific. Also, as Therapeutic Strategy Director he was responsible for designing clinical trial strategies. He has managed more than 10 global clinical trials from phase Ila to phase IIIb, which also included sites in Germany.

Robert has a Master of Business Administration from Aalto University in Finland and a Master of Science from Eberhard-Karls Universitätaet Tuebingen in Germany. His areas of expertise are Clinical Operations Team Management, Clinical Trial Planning and Strategy, Project Management & Trial Oversight, and Clinical Planning & Analytics.
Dr Carolyn Lam is a Senior Consultant of the National Heart Centre, Singapore; Professor of Duke-NUS Cardiovascular Academic Clinical Program; Director of the Clinical & Translational Research Office at NHCS; Scientific Advisor to the Clinical Trials Coordinating Centre at SingHealth and Affiliate Member of the SingHealth Duke-NUS Institute of Precision Medicine. She graduated from the Faculty of Medicine, National University of Singapore, completed advanced specialty training in Cardiology in Singapore, and pursued her Research Fellowship at the Cardiorenal Laboratory, Heart Failure Fellowship at the Division of Cardiovascular Diseases, and Advanced Cardiology and Master of Biomedical Sciences at Mayo Clinic, Rochester MN. She received further training in clinical and genetic epidemiology at the Framingham Heart Study in Boston, MA, graduated from the Stanford Executive Programme and obtained her PhD at University Medical Centre Groningen.

Dr Lam's clinical sub-specialty is heart failure, and she is recognised globally for her expertise in heart failure with preserved ejection fraction. She also has expertise in women's cardiovascular disease, hemodynamics, echocardiography, biomarkers and clinical trials. She started the first Heart Failure with Preserved Ejection Fraction Programme and Women’s Heart Health Clinic in Singapore. She has been recognised by numerous awards, including the NMRC Clinician Scientist Award (2010) for her work in heart failure; the L'Oreal Women In Science Award (2012) for her work in women’s cardiovascular disease and the award for the Junior Chamber International (JCI) Ten Outstanding Young Persons of the World for 2014 – Singapore (2014). She is also a current recipient of the NMRC Senior Investigator Clinician Scientist Award. In 2012, she was named an InterAcademy Medical Panel Young Physician Leader at the World Health Summit in Berlin. She is the Programme Lead of the Asian neTwork for Translational Research and Cardiovascular Trials (ATTRaCT) – an A*STAR Biomedical Research Council-funded research platform and Principal Investigator of an ongoing nation-wide heart failure study in Singapore (the Singapore Heart Failure Outcomes and Phenotypes [SHOP] study) and a multinational Asian study of heart failure across 11 Asian countries (Asian Sudden Cardiac Death in Heart Failure [ASIAN-HF] study). She serves as a consultant on several global advisory boards for cardiovascular disease, as a member of the Executive Committees of global heart failure trials, and as an Associate Editor for Circulation and the European Journal of Heart Failure. Finally, Dr Lam is heard weekly on the global podcast “Circulation On The Run” and seen regularly on television as the Resident Doctor of the health programme “Body and Soul” by MediaCorp Singapore.

Xiangqian is the President and CEO of Esco Group. He is a life sciences entrepreneur and investor with demonstrated track record in scaling up businesses from concept, and has extensive operational and investment experience across the US, Asia and Europe. Since 2000, he transformed his family business into a global life sciences company, and increased its enterprise value 50-100X.

Xiangqian is also the Founding Managing Partner of Esco Ventures, the life sciences investment arm of Esco Group. Focusing on early stage investments in life sciences tools & diagnostics, fertility and women's health and biotech, Xiangqian has invested in more than 10 life sciences start-ups with a total portfolio IRR of approximately 45% to date.

To put Asia's science on the map globally, Xiangqian launched Esco Ventures X to create companies based on platform technologies. Xiangqian is the Co-Founder and Chairman of Carmentix Pte Ltd, which is developing a novel prognostic test to predict the risk of preterm birth in asymptomatic women, currently in large scale global clinical studies. Xiangqian recently co-founded Carmine Therapeutics, a red blood cell gene therapy company with - Prof. Harvey Lodish and Drs. Minh Le and Shi Jiahai, focuses initially on rare diseases, which recently closed an over subscribed seed round.

To pay forward, Xiangqian has established the Esco Ventures Morphosis Fellowship Programme to groom the next generation of life sciences entrepreneurs.

Xiangqian graduated from the Wharton School of Business at the University of Pennsylvania with a BS in Economics and Finance in 2009. He is a father of one, a classical music lover and shuttles between Singapore, China and Boston.
Professor John C W Lim is founding Executive Director of the Centre of Regulatory Excellence (CoRE) at the Duke-National University of Singapore (Duke-NUS) Medical School and Policy Core Lead at the SingHealth Duke-NUS Global Health Institute.

A medical doctor with graduate degrees in Public Health from NUS and Health Policy and Management from Harvard University, Dr Lim is also Chairman of the Singapore Clinical Research Institute and National Health Innovation Centre, Senior Advisor at Singapore’s Ministry of Health (MOH), and Professor of Practice at Duke-NUS and the NUS Saw Swee Hock School of Public Health.

Formerly Chief Executive Officer of Singapore’s Health Sciences Authority and Deputy Director of Medical Services (Industry & Research Matters) in MOH, Professor Lim has also held other senior positions in the health and education ministries. In his current roles, he draws on his international experience and networks to enhance health regulatory and systems capacity and scientific excellence for national authorities, industry and researchers in the Asia-Pacific and South-East Asia.

He is a member of the Executive Board of the APEC Life Sciences Innovation Forum, Advisory Group of the US Pharmacopoeia’s Quality Institute, Scientific Advisory Council of the Centre for Innovation in Regulatory Science, ASEAN Diagnostics Development Initiative Strategic Planning Panel, Board of the Singapore Food Agency and Board of St Andrew's Mission Hospital in Singapore.

In 2018, Professor Lim received the Drug Information Association’s Global Connector Inspire Award for leadership in promoting global collaboration to advance healthcare products to patients, and the Regulatory Affairs Professional Society’s highest Founder’s Award recognising substantial sustained impact in shaping regulatory practice and policy over the course of his career.

Fiona is a Senior Manager at the SingHealth Medical Technology Office (MTO), a one-stop point of contact for collaborators and companies to work with SingHealth clinicians on early-stage to mature medtech innovation projects. From a background in the defence industry, Fiona joined the 2011 batch of Singapore Stanford Biodesign (SSB) Fellows and completed a year-long program in medtech innovation at Stanford University and in Singapore.

After graduation, she became a consultant to A*STAR, where she managed a multi-site clinical trial project. She also consulted for Covidien (now Medtronic) and the Singapore General Hospital (SGH) before joining SingHealth full-time. Fiona supports the newly-rebranded Singapore Biodesign (SB) program as Co-Curriculum Head in curriculum guidance and teaching roles where she co-conducts Biodesign training seminars with other SB trainers. Fiona is a named co-inventor on 3 medical devices with 5 granted patents internationally. She holds B.S. and M.S. degrees in electrical engineering from Stanford University.
Michael Howard Merson, M.D.

Michael H. Merson, M.D., is the founding director of SingHealth Duke-NUS Global Health Institute and the Wolfgang Joklik Professor of Global Health at Duke University. He served as the founding director of the Duke Global Health Institute from 2006-2017, Vice President and Vice Provost for Global Affairs from 2011 -2018 at Duke University, and as Vice Chancellor for Duke-National University of Singapore Affairs from 2010-2016.

In 1978, he joined the World Health Organization (WHO) as a Medical Officer in the Diarrheal Diseases Control Program. He served as Director of that Program from January 1980 until May 1990. In August 1987, he was also appointed Director of the WHO Acute Respiratory Infections Control Program. In May 1990, he was appointed as Director of the WHO Global Program on AIDS. This Program was operational worldwide and responsible for mobilizing and coordinating the global response to the AIDS pandemic.

In 1995, he joined Yale University School of Medicine as its first Dean of Public Health and as Professor and Chairman of the Department of Epidemiology and Public Health. In 2001, he was named as the Anna M. R. Lauder Professor of Public Health in the Yale University School of Medicine. From 1999-2006, he also served as Director of the Center for Interdisciplinary Research on AIDS at Yale University, which undertakes research on HIV prevention in vulnerable and underserved populations in this country and abroad.

Dr. Merson has authored more than 180 articles, primarily in the area of disease prevention. He is the senior editor of Global Health: Disease, Programs, Systems, and Policies, which is a leading global health textbook in the United States. He co-authored the book The AIDS Pandemic: Searching for a Global Response, which examines the 36 year history of the global response to the pandemic. He has served in advisory capacities for UNAIDS, WHO, the Global Fund to Fight AIDS, TB and Malaria, World Bank, World Economic Forum, and the Bill & Melinda Gates Foundation, has two honorary degrees, and is a member of the National Academy of Medicine.

Steven Myint, MD, PhD

Professor Steven Myint MD PhD is a physician with global experience in health and biomedical management. He is currently a Senior fellow to A*star, and consultant to its commercialization arm, Accelerate. He is also Adjunct Professor at Duke-NUS. He is also Chairman of Inex Private Ltd. In the UK he sits on the Boards of the Northern Health Sciences Alliance (part of the UK's Northern Powerhouse project) and a member of the University of Surrey President's advisory team. In Finland he is non-executive director of Aplagon Oy and Medisapiens Oy, both biotech companies. He was also founding partner of the first life sciences Finnish Vigo accelerator, Ukko Partners. He is also Chairman of RT Ventures and Karoo, investment vehicles in life sciences. In addition he is a partner in the Palo Alto based venture fund, Pharma Capital and a non-executive director of Lipid Genomics, a companion diagnostic company spun out of Johns Hopkins, now based in Boston. Until recently he was also executive chairman of Green Signal Bio, which he developed into one of India’s largest vaccine manufacturers. He has held non-executive directorships with several organisations in the public and private sectors.

He is a former Professor and Dean of Medicine & Health at the University of Surrey and Professor/Chairman of Microbiology & Immunology at the University of Leicester in the UK. He has been a biopharmaceutical senior and Board executive as global Medical Director at GlaxoSmithKline and Senior Vice-President for R&D/Chief Medical Officer at BTG International. He was an NHS consultant in UK for over 20 years and is also a former Senior Independent Director, then chairman, of a hospital in the NHS and Board Member of Care International. He also has experience in the IT sector as executive chairman of Onmedica Group Ltd and Onmedica India Private Ltd (a health/IT and marketing organization). He has also been Chief Executive of a patient organization, the European Federation of Neurological Associations, consultant to several organisations in the medical and financial worlds and member of several national and international advisory boards. He has authored over 120 peer reviewed publications and 6 books. He was also Editor-in-Chief of the Journal of Infection for 5 years. He is a Fellow or Member of several societies, including the Institute of Knowledge Transfer, the Royal College of Physicians and the Royal Society of Medicine. After his own first university spinout in 1995, he has been involved in the development of over 30 SME’s in life sciences and created over $1billion value for shareholders.
Assoc Prof Ng Kee Chong graduated from the Faculty of Medicine, National University of Singapore in 1989. He pursued specialty training in Paediatrics and joined KK Women’s and Children's Hospital (KKH) in 1997. He was awarded a Ministry of Health (Singapore) fellowship in post-graduate training (1998-1999) at the Hospital for Sick Children in Ontario, in Paediatric Emergency Medicine. He earned his Master in Business in Business Administration in 2015 from Singapore Management University.

Assoc Prof Ng was Chairman of the Emergency Preparedness Committee at KK Women’s and Children's Hospital (KKH) from 1997 to 2016, leading the hospital's disaster response following the Indian Ocean tsunami in 2004.

He was Head of the Children’s Emergency at KKH from 2005 to 2016, and co-chair of the Ministry Of Health Toxicology Clinical Practice Guidelines Workgroup from 2009 to 2011. With the setting up of the Paediatrics Singhealth Academic Clinical Programme (PAEDS ACP), Assoc Prof Ng was appointed as Chairman from 2011. Assoc Prof Ng was also appointed Chairman, Division of Medicine, KKH, from 2012-2017, and Campus Director of KKH Medical Innovation & Care Transformation, in 2015. He was appointed as Chairman Medical Board 1 May 2017.

Assoc Prof Ng is a member of the Ministry of Health National Trauma Committee, the National Resuscitation Council (NRC) and Chairman of the Paediatric Life Support Subcommittee, NRC. He was appointed to the pro tem committee of the Singapore Resuscitation & First Aid Council (SRFAC) in 2016, and is a member of the International Liaison Committee on Resuscitation (ILCOR) Pediatrics Taskforce.

Assoc Prof Ng is Adjunct Associate Professor with the Duke-NUS Medical School and Yong Loo Lin School of Medicine. He is also a member of the Duke-NUS Medical School Admissions Committee and a council member of the College of Paediatrics & Child Health, Singapore.

Assoc Prof Joanne Ngeow, MBBS, FRCP, MPH

Associate Professor Joanne Ngeow, is a Senior Consultant in Division of Medical Oncology at the National Cancer Centre Singapore (NCCS). Assoc Prof Ngeow currently heads the NCCS Cancer Genetics Service with an academic interest in hereditary cancer syndromes and translational clinical cancer genomics. Her current clinical focus and research revolves around understanding cancer predisposition by studying cancers clustering in families, young adults and in families with multiple / rare cancer presentations.

After completing her undergraduate medical studies at the University of Melbourne, Australia, in 2001, she completed her Internal Medicine training at the Singapore General Hospital and trained in Medical Oncology at NCCS. She was awarded consecutive fellowships by the SingHealth Research Foundation, National Medical Research Council and the Ambrose Monell Foundation to complete formal clinical and bench training as the Ambrose Monell Cancer Genomic Medicine Fellow at the Genomic Medicine Institute, Cleveland Clinic, Ohio. In 2015, she completed her Masters of Public Health at the Bloomberg School of Public Health, Johns Hopkins University, with a focus in cancer epidemiology and health economics making her one of a handful of individuals globally with skills spanning translational science, clinical genetics and health services research.

In 2018, Assoc Prof Ngeow joined Lee Kong Chian School of Medicine as Associate Professor while continuing to lead the clinical cancer genetics service and research programme in inherited cancer syndromes at NCCS. Assoc Prof Ngeow has published over 75 peer reviewed papers in such journals as the Journal of Clinical Oncology, Annals of Oncology, Human Molecular Genetics, Journal of Clinical Endocrinology and Metabolism, Gastroenterology. She is an Associate Editor for Endocrine-Related Cancers.
Vicki Seyfert-Margolis, Ph.D.

Vicki Seyfert-Margolis, Ph.D., founded My Own Med in January 2013, based on over two years of work on a database, web and mobile application platform technology for family-based co-management of health. She has extensive experience from efficacy to effectiveness to clinical trial designs that incorporate digital technology into RWE. Her recent publication in Nature Biotechnology (The Evidence Gap; Vol36 No.3, March 2018) outlines her experience and views on these subjects.

Previously, Dr. Seyfert-Margolis was the Senior Advisor for Science Innovation and Policy in the Office of the Commissioner of the US Food and Drug Administration. While at the FDA, she oversaw the development and execution of an agency wide strategic plan for regulatory science. Prior to the FDA, she served as Chief Scientific Officer at the Immune Tolerance Network (ITN), a non-profit consortium of researchers seeking new treatments for diseases of the immune system. At ITN, Dr. Seyfert-Margolis oversaw the development of over 20 leading edge assay development and centralised laboratory facilities, bringing them to GLP and CLIA compliance. She designed and implemented biomarker discovery studies for over 25 Phase II clinical trials across a broad array of immunologically mediated diseases including autoimmune disorders, allergy, and solid organ transplantation.

Prior to this, she served as Director of the Office of Innovative Scientific Research Technologies at the National Institute of Allergy and Infectious Diseases at NIH, where she worked to integrate emerging technologies into existing immunology and infectious disease programs. Dr. Seyfert-Margolis completed her PhD in immunology at the University of Pennsylvania's School of Medicine, and her post-doctoral fellowship work at Harvard University and the National Cancer Institute.

Vicki Seyfert-Margolis, PhD

SzeKi Sim

A seasoned and passionate marketer, SzeKi joined SGInnovate as part of its pioneer team in Sep 2016. She was entrusted with building the brand and communications team from scratch, to achieve SGInnovate’s mission of enabling ambitious and talented men and women to build, commercialise and scale globally relevant Deep Tech innovations from Singapore. SzeKi also supports these entrepreneurial scientists in crafting, shaping and telling their stories – an important part of their go-to-market journey.

To promote Singapore as a place of thriving innovation in Deep Tech entrepreneurship, SzeKi leads the SGInnovate team in spearheading activities to create a holistic ecosystem, providing a platform where founders, researchers, academics, venture capitalists, corporations come together to share experiences in areas such as Artificial Intelligence, Autonomous Tech, Robotics, MedTech and Quantum Tech.

In less than three years, she has led the establishment of SGInnovate as a leading force in driving Deep Tech innovation and entrepreneurship in Singapore and internationally. SGInnovate has built a thriving community of over 27,000 people from across the ecosystem and clinched multiple awards including the Best B2B PR Campaign (Silver) at the Marketing PR Awards 2017, Outstanding B2B Campaign – Singapore (Merit) and Outstanding Overall Corporate Reputation Programme (Merit) at the PRISM Awards 2019, as well as the Best PR Campaign – B2B (Silver) at the Marketing PR Awards 2019.

Before SGInnovate, SzeKi’s long career in marketing included leading teams with global technology brands such as Hewlett Packard, Motorola and Nokia regionally and globally. Her 15 years at Motorola saw her in various leadership positions including Head of Marketing – Asia Pacific for Motorola Networks, and Head of Marketing – Asia and Middle East for Motorola Solutions. At Nokia Siemens Networks (now Nokia), SzeKi was the Global Head of Customer Marketing for their Global Services organisation.
Kasia Suzor

Kasia Suzor is the co-founder & Chief Executive Officer at Ardion, a biotechnology platform. Kasia is responsible for providing strategic leadership for the company by working with the Board, Scientific Advisory Board and other management to establish long-range goals, strategies, plans and policies. Moreover she focuses on securing funding and navigating the regulatory pathway.

Previously held Managing Director and Partner positions within Hawksburn Capital, managing several investment ventures included life sciences investments, designing and implementing their go-to-market strategies, driving growth and scaling efforts. MSc in Economics and Value based Management.

Soo Khee Chee, MBBS, MD, FRACS, FACS, FAMS

Dr Soo is a surgical oncologist, and Head and Neck surgeon. He was Head of Department of General Surgery at Singapore General Hospital for 11 years and was also the founding director of National Cancer Centre in 1997. His research interest is focused on Biphotonics and running phase 3 clinical trials. Currently he is the Principal Investigator of a clinical trial involving 12 different countries and that has just been completed. He is currently PI with the 10-million-dollar grant from the National Research Foundation leading a consortium on Proton Therapy research. He was the Deputy CEO in charge of research and education at the Singhealth Duke-NUS Academic Medical Centre.

Toh Han Chong, BSc, MB BCHIR, MRCP, FRCP, FAMS

Dr Toh Han Chong is Senior Consultant and Deputy Medical Director, National Cancer Centre Singapore (NCCS). He is Associate Professor at the Cancer & Stem Cell Biology Program, Duke-NUS, and adjunct Principal Investigator, Singapore Immunology Network and Institute of Molecular and Cell Biology, A*STAR.

Dr Toh graduated from the University of London, UK, with an Intercalated Bachelor of Science in 'Infection and Immunity' from St Mary’s Hospital Medical School and qualified as a medical doctor from University of Cambridge, United Kingdom. Dr Toh obtained his Fellowship of the Royal College of Physicians in 2003. He received his medical oncology fellowship training at the Singapore General Hospital, and at the Massachusetts General Hospital, Harvard Medical School, Boston, USA. He then completed a research fellowship in cancer immunotherapy at the Center for Cell and Gene Therapy, Baylor College of Medicine, Houston, Texas, USA. Dr Toh is currently Chief Medical Officer, of Tessa Therapeutics Ltd. He is an alumni of the General Management Program at Harvard Business School.

Dr Toh is a recipient of the National Senior Clinician Scientist Award 2017 for translational research in cancer. He received the National Outstanding Clinician Scientist Award in 2018. Dr Toh has published over 100 peer-review journal articles including in Nature Reviews Clinical Oncology, Nature Genetics, Lancet Oncology, Journal of Clinical Investigation, Journal of Clinical Oncology, Annals of Oncology, PNAS, Clinical Cancer Research. Dr Toh is on the Asia-Pacific Primary Liver Cancer Expert (APPLE) council, founding chairman of the Singapore Cancer Immunotherapy Consortium and on the Cancer Immunotherapy faculty of the European Society of Medical Oncology.
Wong Tien Yin, MBBS, MMed(Ophth), PhD (John Hopkins), FAFPHM, FAMS, FRANZCO, FRCS(Ed), MPH

Prof. Wong is a senior consultant ophthalmologist sub-specializing in medical retina at the Singapore National Eye Centre (SNEC). He is also the Provost's Chair of Ophthalmology at Duke-NUS Medical School, National University of Singapore where he is concurrently Vice-Dean, Office of Academic and Clinical Development.

Prof. Wong is a physician-scientist, practicing as a retinal specialist and with a broad-based research focused on the epidemiology and clinical treatment outcomes of retinal diseases, such as diabetic and hypertensive retinopathy and age-related macular degeneration. He has published more than 1,200 peer-reviewed papers, including papers in the New England Journal of Medicine and the Lancet, has given more than 400 invited named, plenary and symposium lectures. He chairs the International Council of Ophthalmology’s Committee on Diabetic Eye Care, sits on many international professional bodies, and is on Editorial Boards of JAMA Ophthalmology, IOVS, Diabetes Care, and other journals. He is also a two times recipient of the Singapore Translational Researcher (STaR) Award (2008 and 2014), the highest award for the most senior clinician-scientists in Singapore.

Yeo Joo Guan, MBBS, PhD, MRCPCh (UK), MMed (Paeds) (Singapore)

Dr Yeo Joo Guan is a Consultant in Paediatric Medicine in KK Women’s and Children’s Hospital. He earned his M.B., B.S. and Masters of Medicine (Paediatric Medicine) from the National University of Singapore (NUS) in the year 2000 and 2006 respectively. During his advanced specialty training, he obtained his Ph.D. from the Department of Microbiology, Immunology programme, NUS, on the role of serine protease C1s in lupus pathogenesis supported by the Ministry of Health’s Healthcare Research Scholarship in 2014.

Following the completion of his advanced specialty training in 2015, he was mentored by Professor Salvatore Albani (Translational Immunology Institute), working on the holistic, multi-dimensional interrogation of the immunome of childhood onset Systemic Lupus Erythematosus with the dual translational goals of identifying predictors of clinical fate and novel therapeutic targets for manipulation.

He is happily married with 6 children and has a supportive wife seeing him through his endeavour to become a successful clinician scientist with the hope of making a difference in improving the care of paediatric rheumatological patients through translational medicine.

In his free time, he is actively involved in organising outdoor scouting activities for children as a volunteer adult leader. He believed that influencing the next generation either through a holistic education in non-academic skills, in addition to his work as a researcher are important life goals that are worth pursuing.
Participant Biographies
Asaad Tageldein Idris Abdelhalim

I am qualified in Medicine and Basic Sciences from Omdurman Islamic University (Sudan) in 2013. Now, I am doing a Clinical MD immunology Training Program at Sudan medical council. As well as, I am doing a Master of molecular Medicine at university of Khartoum , Sudan .

My research interests span a wide with focus on understanding the role of immune system in Autoimmunity, Allergy and Transplantation. I have a particular interest in the use of Flow cytometry as diagnostic tools for immunological disorders.

Hairil Rizal Bin Abdullah

As a perioperative physician, Dr Hairil is passionate about improving outcomes of patients undergoing surgery. He led the team which revamped the preoperative process in SGH, resulting in the creation of Preoperative Assessment Centre, which is a one-stop multidisciplinary centre to assess and optimise patients prior to elective surgeries. He has also championed multiple perioperative initiatives in this 1800-bedded hospital, such as perioperative Patient Blood Management program and Enhanced Recovery After Surgery pathways.

On the research front, Dr Hairil has led multiple studies examining new approaches in perioperative risk assessment and risk mitigation strategies. He is currently the PI for a large data study involving nearly 200,000 surgical patients in SGH, which has provided insights on how the perioperative outcomes can be improved.

Ali Sulaiman Ali Almelaih Alfazari

Dr. Ali Alfazari is an American and Canadian Board-Certified physician. He completed his internal medicine residency at the Queen Elizabeth II Hospitals in Halifax, Nova Scotia, Canada and subsequently pursued his Gastroenterology training at the Civic and Ottawa General Hospitals in the Canadian Capital City, Ottawa, in addition to the Western General Hospital in Toronto, Ontario. Dr. Ali is a Fellow of the Royal College of Physicians and Surgeons of Canada and the American College of Physicians and the Royal College of Physicians in Glasgow. His academic work and clinical experience are vast.

Dr. Ali is an active academic physician with a passion to teach gastroenterology to students and junior doctors. He been involved in the development of clinical internal medicine residency program in Al Ain and was the Chairman of the Postgraduate Medical Education Committee at the College of Medicine and Health Sciences.

He presented at numerous regional and international conferences. He is the founding and current President of the Emirates Digestive Diseases International Conference, which is held every 2 years in the United Arab Emirates. He has published in numerous peer-reviewed journals. His clinical research interests range from inflammatory bowel diseases, gastritis, obesity and carcinogenesis.
Chew Guojun Gabriel

Gabriel is currently a 5th year MD-PhD student under the supervision of A/Prof Enrico Petretto at the Systems Genetics Lab, Duke-NUS Medical School. He focuses on computational systems biology of Alzheimer’s Disease with an emphasis on single-cell transcriptomic analysis. Through the A*STAR National Science Scholarship, he received his B.Sc in Biomedical Engineering from Johns Hopkins University (2014) where he was awarded the Richard J. Johns Award for highest honours. A tinkerer at heart, he experienced his first highs and lows of biomedical entrepreneurship as part of biomedical design team at Hopkins for his work on reducing endotracheal tube dislodgement during paediatric single-lung ventilation.

During which, he also spent a summer at Ecole Polytechnique De Lausanne learning the basics of building biologically-inspired robots. Recently, his interests have shifted to the use of computational tools and data science in medicine. He looks forward to residency upon graduation, and, of course, the long, tedious but rewarding journey to being a clinician-scientist.

Chong Jun Hua

I am a Cardiologist at the National Heart Centre Singapore, aspiring to be a Clinician Scientist conducting clinical trials to improve cardiovascular outcomes in Asia and establish international thought leadership in ischaemic cardiomyopathy and the emerging field of Cardio-Oncology. I have completed my cardiovascular medical training in Sydney and Melbourne and then a Fellowship in Multimodality Cardiovascular Imaging and Cardio-Oncology at Barts Heart Centre, London. In addition to my clinical work as a Cardiologist, I am also currently undertaking a PhD in Clinical Sciences at Duke NUS Medical School.

Through my PhD projects, I will be looking to improve acute myocardial infarction outcomes by reducing myocardial infarct size and preventing adverse cardiac remodelling through the use of pharmacological and telemedicine strategies. Current knowledge on management of ischaemic heart disease and heart failure have been derived from trials that have traditionally excluded cancer patients. I also intend to address this gap through clinical trial research in the subspecialty of Cardio-Oncology.

Chua Mei Chien

Dr Chua Mei Chien is a Senior Consultant and Head, Department of Neonatology and Director, KK Human Milk Bank in KK Women’s and Children’s Hospital (KKH). Her special area of interest is in neonatal nutrition, breastfeeding and the impact of nutrition on long-term health. She has led in efforts to develop multidisciplinary, evidence-based protocols for nutritional management of preterm infants. She established Singapore’s first donor human milk bank programme in August 2017 which has benefitted more than a thousand vulnerable babies since. She is the principal investigator of a number of industry – sponsored as well as investigator initiated clinical trials. Her latest publication in the Annals of Nutrition and Metabolism is entitled “Asia Pacific Consensus on Perinatal Nutrition and Breastfeeding”.
Deng Xiao

I had 4-year clinical service experience, working as a Neurologist in the First Affiliated Hospital of Guangxi Medical University after I received my master degree of Neurology in China. I joined National Neuroscience Institute (NNI) since 2014, working as a clinical research staff. In the past 4 years, I had more than 15 publications including papers published in prestigious journals such as JAMA neurology, Journal of Medical Genetics and Brain.

I am eager to attend various professional conferences/ workshops and communicate with peers. Over the past 4 years, I have attended more than 15 international conferences and presented my research findings by poster or orally. I was the gold and silver awardee of clinical research presentation in NNI in 2015 and 2016. I was awarded the Talent Development Fund from SingHealth to pursue PhD degree in 2018. Currently I am a year 1 student in Clinical Science PhD programme at Duke-NUS. My research interests is neuromuscular and neurodegenerative diseases. I would like to explore more in the area of clinical neurological research and health service research.

Goh Qing Yuan

I am an Anaesthesiologist and Intensivist in the Surgical Intensive Care Unit of Singapore General Hospital (SGH). I am currently involved in several research projects ranging from observation studies, therapeutic drug trials, validation of diagnostic host-response PCR assay to cost-effectiveness study on rapid diagnostic test. I have an interest in the discovery of new medical knowledge and novel treatment for diseases. I believe that identification of biomarkers for diagnosis and thereby enabling targeted therapy in the ICU is an exciting area that is full of untapped potential.

Prasad Ramanakrishnan Iyer

I am a Consultant at the Children’s Cancer Centre at KK Women’s and Children’s Hospital, Singapore.

After completing my post-graduate training in Paediatrics in India, I went to the UK and completed my advanced specialist training in Manchester. I complemented this training with a further four years in paediatric and adolescent oncology at The Great North Children’s Hospital (Royal Victoria Infirmary), Newcastle upon Tyne and was conferred the Fellowship of the Royal College of Paediatrics and Child Health. My area of clinical interests includes teenage and adolescent cancers. Besides treating solid tumours, I also manage leukaemia, lymphoma and have a keen interest in haematopoietic stem cell transplantation.

Main focus includes late-effects of cancer treatment and modern cellular therapies. In particular I wish to add to the knowledge base of premature ageing in survivors of childhood and adolescent cancers. This research will hopefully give new information to the treating physicians to design clinical trials that use cytotoxic agents more carefully in the future as well as incorporate innovative therapeutics and precision oncology in newer treatment models without compromising and hopefully improving on cure rates. In the long term, I wish to be part of an early phase trials unit in Singapore focusing on precision oncology as well as low toxicity therapeutics in children and adolescents.
Jiang Yingjia, Master in paediatric, chief physician, Vice medical president, the 10th batch of candidates for academic leaders in Sichuan Province, the 10th batch of academic leaders of Health and Family planning Commission of Sichuan Province, major: pediatrics.

As the director of critical and emergency department, she took part in the contingency rescue in the accident of Melamine contamination of dairy products, H1N1 outbreak in 2009, outbreak of hand-foot-and-mouth disease in 2010, and 5·12 earthquake. Since she was appointed as director in charge of PALS (Paediatric advanced life support) in 2008, she has been dedicated to promoting advanced technology in PALS in Sichuan Province. She has undertaken 5 province or department-level scientific research projects and published 20 papers, including Application of analysis of data base and policy making in the construction of digital maternal and child healthcare institutes, Research on mode of grassroot-oriented PALS training.

Fatma Abdul Baqi Mohammed Saleh Al Jasmi

Dr. Al Jasmi is Chair of Genetic & Genomic department, Associate Professor at College of Medicine & Health science, UAE University, Al Ain and Metabolic consultant at Tawam Hospital. She did her undergraduate studies at UAE University, UAE and graduated in 2000 with bachelor in Medicine and health science. She pursued her postgraduate studies at University of Toronto, and Hospital for Sick Children, Canada. In 2006, Dr. Al Jasmi received Canadian Board of Pediatrics after completing the Paediatric residency program. Subsequently, she did her fellowship in biochemical genetics and in 2008 she was certified with Canadian College of Medical Genetics Board (Biochemical Genetics).

Her main research interest is designing and developing Hunter e-Clinic teaching software, which is supported by grant from Shire and translated to Japanese with support of Japanese MPS society and genzyme.

Her Current research:
- The use of Forced Oscillation Technique (FOT) in patients with Lysosomal Storage Diseases
- Methylcitrate to citrate ratio as a diagnostic and monitoring biomarker of inborn errors of propionate metabolism
- Oxygen analyser as a screening tool for disorders of impaired cellular bioenergetics
- Mitochondrial DNA variation in UAE
- Newborn screening of inborn errors of metabolism
- Whole exome sequencing diagnosis of Inborn errors of Metabolism

Jiang Yingjia

Jiang Yingjia, Master in paediatric, chief physician, Vice medical president, the 10th batch of candidates for academic leaders in Sichuan Province, the 10th batch of academic leaders of Health and Family planning Commission of Sichuan Province, major: pediatrics.

As the director of critical and emergency department, she took part in the contingency rescue in the accident of Melamine contamination of dairy products, H1N1 outbreak in 2009, outbreak of hand-foot-and-mouth disease in 2010, and 5·12 earthquake. Since she was appointed as director in charge of PALS (Paediatric advanced life support) in 2008, she has been dedicated to promoting advanced technology in PALS in Sichuan Province. She has undertaken 5 province or department-level scientific research projects and published 20 papers, including Application of analysis of data base and policy making in the construction of digital maternal and child healthcare institutes, Research on mode of grassroot-oriented PALS training.

At present, she assumes the following academic posts: member of Hyperbaric Oxygen Committee of Sichuan Provincial Medical Association, member of Pediatrics Committee of Sichuan Provincial Medical Association, member of Emergency Committee of Sichuan Provincial Medical Association, Paediatric Respiratory System Committee, the 1st Paediatricians Committee of Sichuan provincial Doctors association, member of editorial board of China Maternal and Child Healthcare, the member of the 5th corresponding team of China Paediatric Emergency, reviewer of China Maternal and Child Health. She was awarded as Eminent person in the fight against SARS by Guangdong province, Eminent Party member of fight against natural disasters by Sichuan province, Excellent person for maternal and child healthcare, the nominator for the 5th Chinese Excellent doctors by China Doctors Association, Eminent trainer in neonatal asphyxia resuscitation by Health Ministry successively.
Dr Agnes Koong joined SingHealth Polyclinics in 2006. She completed her post-graduate training in 2014, and is now a fellow of the College of Family Physician Singapore.

Between October 2012 and June 2019, she was Clinic Director of Marine Parade Polyclinic. She played a major role in the redevelopment of the facility in 2015 and pioneered the Patient Ambassador Volunteer program, where volunteers are recruited and trained to improve the care experience of patients in the polyclinic. The program has since been rolled out to more SingHealth Polyclinics. Since July 2019, she has been appointed the designate Clinic Director of Tampines North Polyclinic.

A firm believer of patient empowerment and with a special interest in chronic disease management, she has been involved in the development of initiatives such as the TeleCare program where patients receive care remotely, as well as the SingHealth Polyclinics Care Management Program where care is better co-ordinated for patients with complex care needs.

Her interest and area of focus in the coming years is on population health. She is leading an initiative in the Marine Parade Community, where Primary Health Care providers and partner Community providers to better address the medical and social needs, of a panel of residents with complex needs. She will also be leading a population health effort to improve health outcomes for residents living in the town of Tampines North where the new polyclinic will be slated to open in 2022.

She has been actively involved in undergraduate teaching and was recently appointed Adjunct Assistant Professor in Duke-NUS Medical School. She is also supervisor to trainees of the Fellowship Program organised by the College of Family Physician Singapore.

She was awarded the research training fellowship grant by the National Medical Research Council and will be embarking on her PhD training in August 2019. Her interest is in Health Service Research. She will focus on patients with complex care needs, to evaluate the effectiveness of the Primary Care based integrated care team intervention, and to apply the implementation science framework and methodology in the course of her research.

Dr Sean Lam is an experienced data scientist, practitioner and academician with a PhD and Masters in Operations Research and Decision Science. He has spent nearly 20 years in government, research, academic and healthcare organisations. He is currently the Head of Data Science with the SingHealth Health Services Research Centre (HSRC), overseeing a team of data scientists in the development data science-related infrastructure, technologies, policies and processes for the enhancement of patient care and outcomes. He is also a faculty member with the Duke-NUS Medical School and the Singapore Management University.
Dr. Liu Yong is the director of intensive care unit (ICU) at the Shenzhen Hospital of Southern Medical University. He is a leader in the development of Extracorporeal membrane oxygenation (ECMO) in Shenzhen city. Dr. Liu's team provides ECMO services for adults and paediatric patients in the Shenzhen city. In addition, he has authored numerous studies on the artificial liver, Xenon gas inhale devices.

Dr. Liu's latest research focuses on predicting the prognosis of acute respiratory distress syndrome (ARDS) and acute kidney injury (AKI) by machine learning. The research has developed and validated a mortality predictive method for ARDS or AKI patients based on machine learning models by applying the Medical Information Mart for Intensive Care (MIMIC-III) and the eICU Collaborative Research Database (eICU-CRD) databases. Compared with the existing scoring systems, the model significantly improved the performance on predicting mortality in ARDS or AKI patients. The validation based on a multi-source dataset showed relatively robust generalisation ability of our prediction model.

Dr. Liu is currently the Vice President of the Shenzhen Medical Association of Critical Care Medicine and the member of several society of critical care medicine in local city. He completed his Ph.D. in medicine at the Southern medical university. He created and served in the ICU of Shenzhen hospital of southern medical university since 2015.

---

Dr. Lee Yi Lin is an Associate Consultant anaesthesiologist and intensivist at the Singapore General Hospital. She completed her Anaesthesiology residency programme in SingHealth followed by the local critical care fellowship in 2019. She obtained her MBBS from the National University of Singapore, and went on to qualify for the MRCP (UK) Internal Medicine, MMed (Internal Medicine) in 2014 and MMed (Anaesthesia) in 2015. Her interests are in improving patient care and outcomes and she is currently involved in various research projects within SingHealth.
Loy See Ling

Dr Loy See Ling has been investigating maternal-child nutrition in prospective cohort setting for the past 9 years, specialising in nutritional assessment. Prior to joining KK Women’s and Children Hospital (KKH), she graduated from Universiti Sains Malaysia (USM). Her current interests are chrononutrition, obesity and diabetes.

At KKH, she is the research fellow of Singapore’s pioneering preconception and pregnancy cohort studies Growing Up in Singapore Towards healthy Outcomes (GUSTO), Singapore PREconception Study of long-Term maternal and child Outcomes (S-PRESTO), as well as the international intervention cohort, Nutritional Intervention Preconception and during Pregnancy to maintain healthy glucoSEM levels and offspRing health (NiPPeR). She has published actively in the area of nutritional epidemiology.

She has also received multiple research recognitions included leadership fellowships and awards at various levels (cluster, national, regional, and international) including the SingHealth Publish Award, Nestlé Nutrition Institute Young Researcher Award, Rising Star Award (Japan), Queensland University training fellowship (Australia). In 2018, she has garnered funding of SGD300K through a NMRC Open Fund Young Individual Research Grant (OF-YIRG) as a principal investigator. As a believer in communication and inheriting knowledge to the next generation, she has active interest in education, and have been involved in teaching, and also in bridging the clinical-translational path through dietetic counselling.

Rasha Msallam

I received my diploma as a dentist surgeon from Tishreen university/Syria in 2006. After doing one-year internship at maxillofacial surgery department in Damascus hospital, I was selected by the Syrian ministry of high education as an assistant professor, and joined the oral pathology department of faculty of dentistry in Tishreen university. In 2009, I got a joined scholarship from Syrian ministry of high education and French ministry of research, and moved to Paris to proceed my masters and PhD in immunology, at Bio Sorbonne Paris Cite - Paris Descartes. Since 2016, I am a research fellow at Singapore Immunology Network (SIgN). My research’s interest is focusing on understating the mechanisms and the immune cells involved in the development of neonatal and paediatric allergy reactions.

I am also a member of several scientific committees in Singapore such as a secretary of Singaporean Society for Immunology (SgSI), co-vice president of A*PECSS (A*STAR Postdoc and Early Career Scientist, and Society Singapore Women In Science (SgWIS).
Katherine Nay Yaung

Katherine is an MD-PhD student at Duke-NUS Medical School. She is currently in her 2nd year of PhD studies in Professor Salvatore Albani's laboratory at the Translational Immunology Institute (TII). She has a keen interest in translational research and is excited to learn more about its nuances through the Merlion School. Her research interests are broad, including but not limited to: immunology, metabolism, neurobiology, regenerative medicine and rheumatology. As for clinical interests, Katherine is keeping an open mind and has given some thought to obstetrics & gynaecology, paediatrics and psychiatry.

Miina Öhman

Dr. Miina Öhman is originally from Finland where she studied at University of Helsinki receiving her MD degree, as well as PhD in genetics of obesity. After working as a clinician in Emergency Medicine and Primary Care, she moved to the United States to pursue postdoctoral research at University of Michigan Cardiovascular Research Center. She studied molecular mechanisms linking adipose tissue inflammation and atherosclerosis, and developed a novel in vivo model to study plaque instability induced by inflammatory visceral fat.

After 10 years in Michigan, Dr. Öhman returned to Finland in 2011. She relocated to Singapore in 2012 due to family reasons and started working in Cardiovascular and Metabolic Disorders Programme at Duke-NUS Medical School. In Singapore, she has collaborated with clinicians from Singapore General Hospital and University of Helsinki to study diabetic nephropathy. She has also investigated novel methods to culture pancreatic islets to increase the efficacy of islet transplantation to diabetic patients.

Dr. Öhman has 25 peer-reviewed publications and she recently received NMRC's Clinician Scientist New Investigator Grant to establish her in vivo model to study atherosclerotic plaque rupture and novel plaque stabilising therapies. Dr. Öhman is married and mother of two teenage girls.

Ong Chengsi

Chengsi completed her undergraduate degree in dietetics and Masters in Public Health nutrition in the United States, before returning to Singapore to practice as a clinical dietitian at KK Women's and Children's Hospital, Singapore. She has been working with women and children for the past 10 years, and currently specialises in nutrition in critically ill neonates and children.

Chengsi's research interests include nutrition support, muscle and body composition, and patient reported outcomes. She has been involved in several studies on malnutrition and nutritional optimisation in children. For the past few years, Chengsi has been pursuing a PhD at the National University of Singapore, exploring the role of malnutrition and muscle wasting in association with functional impairment in critically ill children. She is also currently involved in the KK Human Milk Bank, and hopes to further explore the role of donor human milk in optimising outcomes in sick children.
Zayim Razîna D/O Seeni Syed

Graduated from Nanyang Technological University, Singapore with a PhD in Bioengineering in 2019. Her research interest is in the field of medical technologies for drug delivery in transdermal/transmucosal applications. Currently, she is working on a minimally invasive drug delivery platform using microneedles for painless dental anaesthesia and looking forward to commercialisation in the near future.

Soh Yu Qiang

I am an Ophthalmologist by training, currently pursuing a PhD in clinical sciences at Duke-NUS. Medicine has progressed significantly over the years and there are now cures and solutions to diseases which one would not have dreamed of just half a century ago. Translational research drives the progression from benchside experiments to real-life healthcare solutions. However, efforts at translational research often appear to be disjointed, with multiple involved parties each having seemingly disparate interests – academics yearning for the next high impact publication, clinicians desiring to bring new therapeutics to their patients as quickly as possible, institutions clamouring for intellectual property, and financiers gunning for the next big unicorn disruptor. Translational research will undoubtedly benefit from greater synergy amongst these parties. Through my participation in the Merlion School, I hope to achieve a greater visibility into the activities which happen on ‘the other side of the fence’, and to acquire skills and networks which will accelerate my career as a clinician scientist in the field of translational research.

Aaron C. Tan

Aaron is currently an Oncology Fellow at the National Cancer Centre Singapore (NCCS), having completed his specialty training in Medical Oncology in Sydney, Australia. He has a background in basic sciences research having completed a PhD in drug discovery and molecular pathways of carcinogenesis at The University of Sydney. At NCCS, he is completing a fellowship in early phase trials and lung cancer translational research. This includes an International Association for the Study of Lung Cancer (IASLC) Fellowship 2018-2020, which provided funding for a study of liquid biopsies in resected early stage lung cancers. He also has a keen interest in clinical trials and developed a protocol for a multi-centre phase 2 trial of dacomitinib in advanced EGFR mutant NSCLC, which is being co-ordinated by the Asian Thoracic Oncology Research Group (ATORG) – a co-operative lung cancer trials group in Asia.
Tay Shi Huan

Hello! I am Shi Huan, a MD-Ph.D. candidate at Duke-NUS Medical School, working on juvenile idiopathic arthritis under the tutelage of Prof. Salvatore Albani. Prior to Duke-NUS, I did Natural Sciences Tripos in Cambridge, where my final year project was on norovirus biochemistry, and I subsequently spent a year at the Clinical Nutrition Research Centre (A*STAR) looking at brown adipose tissue biology. I must say that I am really excited to attend the Merlion School and interact with many brilliant minds! The inherent fluidity of research excites me, and as I grow in both the clinical and scientific worlds, I increasingly appreciate how failure provides the basis on which new findings flourish. I hope to, in time to come, be able to drive innovation for the betterment of lives.

Carla Bianca Luena Victorio

Mabuhay! I am Bianca, a postdoctoral research fellow in the Laboratory for Translational and Molecular Imaging (LTMI) at Duke-NUS Medical School. My name, which is confusing to most people, is a Filipino name. I am from the Philippines and moved to Singapore for post-graduate studies. I recently obtained my PhD from NUS Yong Loo Lin School of Medicine in 2017 and, prior to that, also obtained a joint MSc degree from the same Institute and University of Basel, Switzerland in 2011.

I am deeply interested in translational research in Infectious Diseases and have worked on various topics ranging from Parasitology to Veterinary Virology to Clinical Virology. I had previously trained as a molecular biologist, virologist, and experimental animal pathologist and worked on projects involving development and evaluation of animal models of infection. Currently, I am training as an Imaging Scientist focused on applying nuclear and molecular imaging tools to aid studies in viral pathogenesis and therapeutics development. My current research interests include the development of imaging biomarkers that could be used as surrogate for monitoring clinical infectious disease and response to therapeutic interventions. I am also developing viruses with oncolytic potential against glioblastoma tumours and which can be tracked non-invasively with nuclear imaging modalities (PET/SPET/CT).
Dr. Wong is a Senior Consultant Paediatrician in the Departments of Child Development and Neonatology, KK Women's and Children's Hospital (KKH), Singapore. She was accredited as a Specialist in Paediatric Medicine and Neonatology in 2010 by the General Medical Council, UK. She is a Fellow of the Royal College of Paediatrics and Child Health, UK (FRCPCH) and a Fellow of the Academy of Medicine, Singapore (FAMS). Dr. Wong was also awarded a Doctor of Philosophy (PhD) in Medicine by research in 2006. She joined KKH in 2011, having previously worked in Paediatrics in the UK since 1997.

Dr. Wong is also a Senior Clinical Lecturer with the NUS Yong Loo Lin School of Medicine and an Adjunct Assistant Professor with the Duke-NUS Graduate Medical School and Lee Kong Chian School of Medicine. She has served on the SingHealth research ethics Centralised Institutional Review Board since 2014.

Dr. Wong's sub-specialty interests include autism spectrum disorder and the effect of screen time and sleep on children with developmental disorders, and her PhD was in neonatal pain. She is certified in both Bayley and Griffiths Scales of Child Development, as well as the Autism Diagnostic Observation Schedule (ADOS) and Autism Diagnostic Interview, Revised (ADI-R) diagnostic tools for autism. Dr. Wong has led the Autism Track Services at KK Hospital since 2013 and has worked to improve waiting times for access to autism diagnostic services, and developed various workflows and patient education leaflets to improve clinical services.

Dr. Wong has also completed various research projects on autism, such as to explore coping strategies amongst parents of children newly-diagnosed with autism, the impact of DSM-5 diagnostic criteria changes on Singaporean patients, and the impact of screen time on sleep and emotional/behavioural difficulties in preschool children with neurodevelopment disorders. She is currently investigating the outcomes of a cohort of 2008 to 2011-born children with autism. Her latest projects have been to establish a programme for screening infant siblings of children with autism, and to start a clinical trial on autologous umbilical cord blood reinfusion as a treatment for autism (in collaboration with Duke University).

Dr. Wong is a member of the International Society for Autism Research (INSAR), Australasian Society for Autism Research (ASFAR), the Singapore Paediatric Society, and the Neonatal Society, UK.

Dr. Xiao Bing, Senior consultant of Ob/Gyn. He was graduated from West China University of Medical Sciences(WCUMS) in 1998, and got the Bachelor's Degree of Medicine. After then, He continued his postgraduate education in WCUMC, and he got the Master Degree of Medicine in 2001. His major is Maternal-Fetal Medicine. He joined the Sichuan Provincial Women & Children Hospital from 2001. The hospital is the only provincial level and tertiary hospital for Women & Children in Sichuan Province. He had completed his residency and chief residency training in this hospital.

In 2008, he became the vice consultant of Ob/Gyn and dean of the Department of Obstetric. During his clinical practice, he concerned more about pregnancy hypertensive diseases and gestation diabetes mellitus. He built the maternal intensive care unit in the hospital for critical obstetric patients. He became the Senior consultant in 2013. In 2014, he left Sichuan provincial Women & Children hospital then joined the Angel Hospital for Women & Children, which was a private hospital and the only hospital accredited by JCI in Chengdu, Sichuan. He had spent 4 years in Angel Hospital, 3 years as the dean of Dept. Ob/Gyn, and 1 year as the chief medical officer. He helped the hospital constructed the residency and chief residency training system and auditing of critical cases. As the CMO, he leaded the medical team passed the reaccredited by JCI with very high score. In 2018, Dr. Xiao Bing joined the Minerva Hospital for Women & Children as the dean of Dept. Obstetric.
I come from northeast of China and graduated from China medical university in 2004. I have been working in Shengjing Hospital as a paediatrist for 15 years and I am an attending doctor in paediatric intensive unite now. I am good at diagnosis and treatment of common critical illness, especially in sepsis, septic shock. My Ph.D. research of interest is sepsis-induced myocardial dysfunction in children, and I have done both clinical and basic researches in recent years.

Carol Yu is a cell biologist and molecular neuroscientist with over 15+ years of diverse multi-disciplinary experience in organisms such as bacteria, yeast, fruit flies, mouse and human primary cell cultures, managing pre-clinical R&D projects that aim at novel therapeutic strategies for drug discovery of acne and sebum control. She is an engaging and passionate communicator in oral and written science, establishing a solid basis of confidence and respect among stack-holders and collaborators, and realizing scientific concepts to audiences of diverse backgrounds. She also has an outstanding soft skill sets in communication and team work, understanding the market knowledge with analytical skills, communicating the need, negotiating the best business deals, finding a solution while maintaining and developing professional relationships with key opinion leaders and stack-holders.

Born in Macau S.A.R, China, Carol obtained her undergraduate degree in Life Sciences from the National Yang Ming University, Taipei, Taiwan. With her interest in Neuroscience, she was awarded the Excellence Scholarship of Utrecht University, the Netherlands to pursue her master degree in Neuroscience & Cognition. During her research internship with Dr. Dick Jaarsma and Dr. Casper Hoogenraad, she became very interested in the molecular mechanism of intracellular trafficking and started her graduate training with a focus on biochemical and molecular characterization of exocytosis under the supervision of Prof. Anna Akhmanova at Erasmus Medical Center, Rotterdam, she then moved with Akhmanova Lab to Department of Biology, Faculty of Science, Utrecht University in 2011 and obtained her PhD in 2015 from the Utrecht University.

In April 2015, Carol relocated to Singapore join Dr. Lim Xinhong and Prof. Maurice van Steensel to study hair follicle stem cells and sebaceous glands in the Institute of Medical Biology (IMB), A*STAR and Skin Research Institute of Singapore (SRIS), A*STAR. She has been leading research projects in understanding the physiology, chronobiology of the sebaceous glands as well as the control of sebum release using mouse genetics and in vitro models of murine and primary human sebocytes cultures.

Outside the lab, Carol is the event lead for science career-related events and vice president of the A*STAR Postdoctoral and Early Career Research Society (A*PECSS). She has a strong interest in business development, consulting and entrepreneurship in life sciences. She jogs, swims, plays piano and harp, listens to classical and jazz music as her hobbies, and enjoys the nature by hiking and cycling when she is free.
## Participant Grouping

<table>
<thead>
<tr>
<th>Magic Bullet: Case Study Groups</th>
<th>Mentoring \ Design Challenge Groups</th>
<th>Presentation Workshop Groups</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Group 1: Salvatore</strong></td>
<td><strong>Group 1: Salvatore \ Carolyn</strong></td>
<td><strong>Group 1: Salvatore</strong></td>
</tr>
<tr>
<td>Ali Alfazari</td>
<td>Deng Xiao</td>
<td>Rasha Msallam</td>
</tr>
<tr>
<td>Yang Ni</td>
<td>Soh Yu Qiang</td>
<td>Liu Yong</td>
</tr>
<tr>
<td>Gabriel Chew</td>
<td>Mae Wong</td>
<td>Carol Yu</td>
</tr>
<tr>
<td>Prasad Iyer</td>
<td>Goh Qing Yuan</td>
<td>Hairil Rizal Bin Abdullah</td>
</tr>
<tr>
<td>Lee Yi Lin</td>
<td>Chua Mei Chien</td>
<td>Chong Junhua</td>
</tr>
<tr>
<td>Loy See Ling</td>
<td><strong>Group 2: Vicki \ Kee Chong</strong></td>
<td>Sean Lam</td>
</tr>
<tr>
<td><strong>Group 2: Vicki</strong></td>
<td>Ali Alfazari</td>
<td><strong>Group 2: Vicki</strong></td>
</tr>
<tr>
<td>Liu Yong</td>
<td>Yang Ni</td>
<td>Fatma Al Jasmi</td>
</tr>
<tr>
<td>Carla Bianca Victorio</td>
<td>Gabriel Chew</td>
<td>Xiao Bing</td>
</tr>
<tr>
<td>Agnes Koong</td>
<td>Chong Junhua</td>
<td>Zayim Razina D/O Seeni Syed</td>
</tr>
<tr>
<td>Ong Chengsi</td>
<td>Aaron Tan</td>
<td>Soh Yu Qiang</td>
</tr>
<tr>
<td>Tay Shi Huan</td>
<td>Katherine Nay Yaung</td>
<td>Miina Ohman</td>
</tr>
<tr>
<td><strong>Group 3: Wainwright</strong></td>
<td><strong>Group 3: Gordon</strong></td>
<td>Prasad Iyer</td>
</tr>
<tr>
<td>Fatma Al Jasmi</td>
<td>Asaad Abdelhalim</td>
<td><strong>Group 3: Gordon</strong></td>
</tr>
<tr>
<td>Jiang Yingjia</td>
<td>Jiang Yingjia</td>
<td>Gabriel Chew</td>
</tr>
<tr>
<td>Miina Öhman</td>
<td>Prasad Iyer</td>
<td>Yang Ni</td>
</tr>
<tr>
<td>Soh Yu Qiang</td>
<td>Carla Bianca Victorio</td>
<td>Goh Qing Yuan</td>
</tr>
<tr>
<td>Goh Qing Yuan</td>
<td>Sean Lam</td>
<td>Chua Mei Chien</td>
</tr>
<tr>
<td>Aaron Tan</td>
<td>Carol Yu</td>
<td>Tay Shi Huan</td>
</tr>
<tr>
<td><strong>Group 4: Scott \ Gordon</strong></td>
<td><strong>Group 4: Wainwright</strong></td>
<td>Loy See Ling</td>
</tr>
<tr>
<td>Rasha Msallam</td>
<td>Rasha Msallam</td>
<td><strong>Group 4: Wainwright</strong></td>
</tr>
<tr>
<td>Xiao Bing</td>
<td>Xiao Bing</td>
<td>Ali Alfazari</td>
</tr>
<tr>
<td>Hairil Rizal Bin Abdullah</td>
<td>Lee Yi Lin</td>
<td>Deng Xiao</td>
</tr>
<tr>
<td>Chua Mei Chien</td>
<td>Agnes Koong</td>
<td>Asaad Abdelhalim</td>
</tr>
<tr>
<td>Mae Wong</td>
<td>Hairil Rizal Bin Abdullah</td>
<td>Katherine Nay Yaung</td>
</tr>
<tr>
<td>Zayim Razina D/O Seeni Syed</td>
<td>Zayim Razina D/O Seeni Syed</td>
<td>Ong Chengsi</td>
</tr>
<tr>
<td><strong>Group 5: Gianfranco</strong></td>
<td><strong>Group 5 Scott \ Gianfranco</strong></td>
<td>Mae Wong</td>
</tr>
<tr>
<td>Asaad Abdelhalim</td>
<td>Fatma Al Jasmi</td>
<td><strong>Group 5: Scott \ Gianfranco</strong></td>
</tr>
<tr>
<td>Deng Xiao</td>
<td>Liu Yong</td>
<td>Jiang Yingjia</td>
</tr>
<tr>
<td>Chong Junhua</td>
<td>Loy See Ling</td>
<td>Aaron Tan</td>
</tr>
<tr>
<td>Katherine Nay Yaung</td>
<td>Miina Öhman</td>
<td>Carla Bianca Victorio</td>
</tr>
<tr>
<td>Sean Lam</td>
<td>Tay Shi Huan</td>
<td>Lee Yi Lin</td>
</tr>
<tr>
<td>Carol Yu</td>
<td>Ong Chengsi</td>
<td>Agnes Koong</td>
</tr>
</tbody>
</table>
### Course Curriculum

#### EUREKA SINGAPORE

**Merlion School - Translational Medicine**

18 - 22 November 2019 • One Degree 15 Marina (Sentosa), Singapore

**CURRICULUM (as on 5 November 2019)**

*Eureka reserves the right to change any session as deemed necessary.*

<table>
<thead>
<tr>
<th>Time (Start)</th>
<th>Monday, 18 Nov</th>
<th>Tuesday, 19 Nov</th>
<th>Wednesday, 20 Nov</th>
<th>Thursday, 21 Nov</th>
<th>Friday, 22 Nov</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Transport</strong> to</td>
<td>From Harbourfront MRT Station Exit D Taxi Stand: 07:45 Slot</td>
<td>From Harbourfront MRT Station Exit D Taxi Stand: 07:45 Slot</td>
<td>From Harbourfront MRT Station Exit D Taxi Stand: 07:45 Slot</td>
<td>From Harbourfront MRT Station Exit D Taxi Stand: 07:45 Slot</td>
<td>From Harbourfront MRT Station Exit D Taxi Stand: 07:45 Slot</td>
</tr>
<tr>
<td><strong>Registration</strong></td>
<td>08:30</td>
<td>08:30</td>
<td>08:30</td>
<td>08:30</td>
<td>08:30</td>
</tr>
<tr>
<td><strong>Kick Off - Reflection on 18 Nov Session</strong></td>
<td>08:30</td>
<td>08:30</td>
<td>08:30</td>
<td>08:30</td>
<td>08:30</td>
</tr>
<tr>
<td><strong>Meeting</strong></td>
<td>08:30</td>
<td>08:30</td>
<td>08:30</td>
<td>08:30</td>
<td>08:30</td>
</tr>
<tr>
<td><strong>10:00-10:15</strong></td>
<td>10:00-10:15</td>
<td>10:00-10:15</td>
<td>10:00-10:15</td>
<td>10:00-10:15</td>
<td>10:00-10:15</td>
</tr>
<tr>
<td><strong>13:30-15:00</strong></td>
<td>13:30-15:00</td>
<td>13:30-15:00</td>
<td>13:30-15:00</td>
<td>13:30-15:00</td>
<td>13:30-15:00</td>
</tr>
<tr>
<td><strong>15:15-16:45</strong></td>
<td>15:15-16:45</td>
<td>15:15-16:45</td>
<td>15:15-16:45</td>
<td>15:15-16:45</td>
<td>15:15-16:45</td>
</tr>
<tr>
<td><strong>16:00-16:15</strong></td>
<td>16:00-16:15</td>
<td>16:00-16:15</td>
<td>16:00-16:15</td>
<td>16:00-16:15</td>
<td>16:00-16:15</td>
</tr>
<tr>
<td><strong>16:15-17:00</strong></td>
<td>16:15-17:00</td>
<td>16:15-17:00</td>
<td>16:15-17:00</td>
<td>16:15-17:00</td>
<td>16:15-17:00</td>
</tr>
<tr>
<td><strong>16:45-16:15</strong></td>
<td>16:45-16:15</td>
<td>16:45-16:15</td>
<td>16:45-16:15</td>
<td>16:45-16:15</td>
<td>16:45-16:15</td>
</tr>
<tr>
<td><strong>17:15</strong></td>
<td>17:15</td>
<td>17:15</td>
<td>17:15</td>
<td>17:15</td>
<td>17:15</td>
</tr>
<tr>
<td><strong>17:30</strong></td>
<td>17:30</td>
<td>17:30</td>
<td>17:30</td>
<td>17:30</td>
<td>17:30</td>
</tr>
<tr>
<td><strong>18:15</strong></td>
<td>18:15</td>
<td>18:15</td>
<td>18:15</td>
<td>18:15</td>
<td>18:15</td>
</tr>
<tr>
<td><strong>18:30-18:45</strong></td>
<td>18:30-18:45</td>
<td>18:30-18:45</td>
<td>18:30-18:45</td>
<td>18:30-18:45</td>
<td>18:30-18:45</td>
</tr>
<tr>
<td><strong>18:45</strong></td>
<td>18:45</td>
<td>18:45</td>
<td>18:45</td>
<td>18:45</td>
<td>18:45</td>
</tr>
<tr>
<td><strong>19:00</strong></td>
<td>19:00</td>
<td>19:00</td>
<td>19:00</td>
<td>19:00</td>
<td>19:00</td>
</tr>
</tbody>
</table>

---

**Notes:**

- **Transport:** From Harbourfront MRT Station Exit D Taxi Stand: 07:45 Slot
- **Meeting:** 10:00-10:15
- **10:15-11:15:** Drug Development Process Speaker: Vicki Seybert-Margolis
- **11:15-12:15:** Mapping Translational Medicine: Introduction to TM Speaker: Salvatore Albanese
- **11:15-12:15:** Contemporary Clinical Trials I Speaker: Vicki Seybert-Margolis
- **11:15-12:15:** Intellectual Property Speaker: Wainwright Fishburn
- **11:15-12:15:** Building a Deep Tech Ecosystem Speaker: Szakil Sim
- **12:15-13:30:** Lunch
- **12:45-14:00:** Lunch
- **12:45-13:45:** Lunch
- **12:45-14:00:** Contemporary Clinical Trials II Speaker: Robert Kerle
- **12:45-14:00:** Lunch
- **12:45-13:45:** Lunch
Notes